[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 19267
1. Murphy AJ, Wells JC, Williams JE, Fewtrell MS, Davies PS, Webb DK: Body composition in children in remission from acute lymphoblastic leukemia. Am J Clin Nutr; 2006 Jan;83(1):70-4
Hazardous Substances Data Bank. DEUTERIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Body composition in children in remission from acute lymphoblastic leukemia.
  • BACKGROUND: Changes in body composition are commonly reported in pediatric survivors of acute lymphoblastic leukemia (ALL).
  • However, the effect of ALL and of its treatment on body composition in children in remission from ALL has not been fully examined with the use of a reference method.
  • OBJECTIVES: We aimed to determine the body composition and composition of fat-free mass (FFM) in children in remission from ALL.
  • DESIGN: This cross-sectional study measured height, weight, body volume, total body water, and bone mineral content in 24 children in remission from ALL and 24 age-matched, healthy control subjects.
  • Examination of the composition of FFM made it evident that children in remission from ALL had both significantly greater hydration (P = 0.001) and lower density (P = 0.0001) of FFM than did the control children.
  • CONCLUSIONS: Children in remission from ALL may develop excess body fat.
  • [MeSH-major] Adipose Tissue / metabolism. Body Composition. Body Water / metabolism. Muscle, Skeletal / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Absorptiometry, Photon. Body Mass Index. Case-Control Studies. Child. Cross-Sectional Studies. Deuterium. Dexamethasone / adverse effects. Dexamethasone / therapeutic use. Female. Humans. Male. Models, Biological. Plethysmography. Prednisolone / adverse effects. Prednisolone / therapeutic use. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16400052.001).
  • [ISSN] 0002-9165
  • [Journal-full-title] The American journal of clinical nutrition
  • [ISO-abbreviation] Am. J. Clin. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; AR09D82C7G / Deuterium
  •  go-up   go-down


2. Tsuji A, Sasaki M, Ishii T, Sato S, Kanki H, Suzuki S, Takeuchi S, Fukuda T: Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease? Keio J Med; 2010;59(2):64-8
MedlinePlus Health Information. consumer health - Eosinophilic Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent eosinophilic infiltration of the myocardium in a child in complete remission of acute lymphoblastic leukemia and eosinophilia. Potential role in late cardiac disease?
  • This report describes the long-term (23 years) follow-up of a pediatric patient with acute lymphoblastic leukemia and eosinophilia who underwent multiple valve replacements.
  • An 8-year-old boy with this complex disease was admitted in January 1984 and treated with 6-week course of vincristine, L-asparaginase, and prednisolone, which induced complete remission.
  • The present study indicates that a subset of patients in complete remission of acute lymphoblastic leukemia and eosinophilia can show persistent myocardial eosinophilic infiltration and are at risk of late cardiac disease.
  • [MeSH-major] Cardiomyopathies / etiology. Cardiomyopathies / pathology. Eosinophilia / complications. Eosinophilia / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cardiomyopathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20601842.001).
  • [ISSN] 1880-1293
  • [Journal-full-title] The Keio journal of medicine
  • [ISO-abbreviation] Keio J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Mateo J, Abarzuza R, Núñez E, Cristóbal JA: [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission]. Arch Soc Esp Oftalmol; 2007 Mar;82(3):167-70
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Bilateral optic nerve infiltration in acute lymphoblastic leukemia in remission].
  • [Transliterated title] Infiltración bilateral del nervio óptico en un caso de leucemia aguda linfoblástica de células T en remisión.
  • CASE REPORT: An 18-year-old male affected by acute lymphoblastic leukemia (ALL) after having reached complete remission after chemotherapy developed bilateral optic nerve infiltration.
  • [MeSH-major] Leukemic Infiltration. Optic Nerve / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Fatal Outcome. Fundus Oculi. Humans. Male. Papilledema / diagnosis. Prognosis. Recurrence. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17357894.001).
  • [ISSN] 0365-6691
  • [Journal-full-title] Archivos de la Sociedad Española de Oftalmología
  • [ISO-abbreviation] Arch Soc Esp Oftalmol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Hindo H, Buescher ES, Frank LM, Pettit D, Dory C, Byrd R: West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission. J Pediatr Hematol Oncol; 2005 Dec;27(12):659-62
Hazardous Substances Data Bank. ACYCLOVIR .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] West Nile virus infection in a teenage boy with acute lymphocytic leukemia in remission.
  • The authors describe an adolescent with acute lymphocytic leukemia and WNV encephalitis.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. West Nile Fever / complications
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Acyclovir / therapeutic use. Adolescent. Animals. Antibodies, Viral / blood. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Antiviral Agents / therapeutic use. Brain / pathology. Ceftazidime / therapeutic use. Ceftriaxone / therapeutic use. Culicidae. Diagnosis, Differential. Encephalitis, Viral / diagnosis. Fatal Outcome. Humans. Immunoglobulins, Intravenous / therapeutic use. Insect Bites and Stings / complications. Magnetic Resonance Imaging. Male. North Carolina / ethnology. Persistent Vegetative State / etiology. Prednisone / administration & dosage. Vancomycin / therapeutic use. Vincristine / administration & dosage. Virginia. West Nile virus / immunology

  • Genetic Alliance. consumer health - West nile virus.
  • MedlinePlus Health Information. consumer health - West Nile Virus.
  • Hazardous Substances Data Bank. Vancomycin .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16344671.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Viral; 0 / Antiviral Agents; 0 / Immunoglobulins, Intravenous; 5J49Q6B70F / Vincristine; 6Q205EH1VU / Vancomycin; 75J73V1629 / Ceftriaxone; 9M416Z9QNR / Ceftazidime; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone; X4HES1O11F / Acyclovir
  •  go-up   go-down


5. Yang H, Kadia T, Xiao L, Bueso-Ramos CE, Hoshino K, Thomas DA, O'Brien S, Jabbour E, Pierce S, Rosner GL, Kantarjian HM, Garcia-Manero G: Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia. Blood; 2009 Feb 26;113(9):1892-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia.
  • Pretreatment aberrant DNA methylation patterns are stable at time of relapse in acute lymphocytic leukemia (ALL).
  • We hypothesized that the detection of residual methylation alterations at the time of morphologic remission may predict for worse prognosis.
  • We developed a real-time bisulfite polymerase chain reaction assay and analyzed the methylation levels of p73, p15, and p57(KIP2) at the time of initial remission in 199 patients with Philadelphia chromosome-negative and MLL(-) ALL.
  • In 123 (65%) patients, matched pretreatment samples were also studied and compared with remission ones: in 82 of those with initial aberrant methylation of at least one gene, 59 (72%) had no detectable methylation at remission and 23 (28%) had detectable residual methylation.
  • By multivariate analysis, the presence of residual p73 methylation was associated with a significant shorter duration of first complete remission (hazard ratio=2.68, P= .003) and overall survival (hazard ratio=2.69, P= .002).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):547-61 [10653870.001]
  • [Cites] Nucleic Acids Res. 2008 Jan;36(Database issue):D25-30 [18073190.001]
  • [Cites] Hematol Oncol Clin North Am. 2001 Feb;15(1):163-205 [11253606.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Nat Rev Genet. 2002 Jun;3(6):415-28 [12042769.001]
  • [Cites] Clin Cancer Res. 2002 Jun;8(6):1897-903 [12060634.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2217-24 [12114423.001]
  • [Cites] Blood. 2003 May 15;101(10):4131-6 [12586619.001]
  • [Cites] Leukemia. 2003 Sep;17(9):1845-50 [12970785.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1535-48 [15071128.001]
  • [Cites] Blood. 2004 Jun 15;103(12):4396-407 [14551133.001]
  • [Cites] Blood. 2004 Oct 15;104(8):2492-8 [15198948.001]
  • [Cites] Hematol Oncol Clin North Am. 1993 Feb;7(1):139-60 [8449856.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] J Clin Oncol. 2005 Jun 10;23(17):3932-9 [15851765.001]
  • [Cites] Leuk Res. 2005 Aug;29(8):881-5 [15978938.001]
  • [Cites] Blood. 2006 Nov 15;108(10):3271-9 [16882711.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1370-7 [17283175.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1381-96, x-xi [11147229.001]
  • (PMID = 19109226.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA105771; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / CA100067; United States / NCI NIH HHS / CA / R21 CA100067; United States / NCI NIH HHS / CA / CA105771
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p15; 0 / Cyclin-Dependent Kinase Inhibitor p57; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins; 0 / tumor suppressor protein p73
  • [Other-IDs] NLM/ PMC2651008
  •  go-up   go-down


6. Lakshmi C, Srinivas CR: Granuloma annulare - remission with PUVASOL. Indian J Dermatol; 2010;55(1):97-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granuloma annulare - remission with PUVASOL.
  • A 64-year-old man with generalized papular granuloma annulare of four years duration with frequent relapses and remissions presented with persistent lesions while on 15 mg prednisolone and achieved complete remission with PUVASOL therapy using solarium.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Exp Dermatol. 1988 Jan;13(1):26-7 [3208437.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2003 Jan-Feb;69(1):10-1 [17642813.001]
  • [Cites] Br J Dermatol. 2001 May;144(5):996-9 [11359387.001]
  • [Cites] Arch Dermatol. 1990 Mar;126(3):356-8 [2138005.001]
  • (PMID = 20418988.001).
  • [ISSN] 1998-3611
  • [Journal-full-title] Indian journal of dermatology
  • [ISO-abbreviation] Indian J Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2856384
  • [Keywords] NOTNLM ; Bath-PUVA / granuloma annulare / solarium
  •  go-up   go-down


7. Shammas RM, Ranganath VK, Paulus HE: Remission in rheumatoid arthritis. Curr Rheumatol Rep; 2010 Oct;12(5):355-62
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in rheumatoid arthritis.
  • With advancing therapeutic options, achieving a state of remission has become the treatment goal in rheumatoid arthritis.
  • Agreeing on what constitutes remission and what measures should be used to assess disease activity has remained a challenge.
  • Multiple remission criteria have been devised and modified, all with different strengths and limitations.
  • A consensus definition of remission will need to be achieved if we are to be able to evaluate outcomes of clinical trials and establish treatment targets for practice.
  • Remission defined as the complete absence of disease currently may not be a realistic therapeutic goal.
  • [MeSH-minor] Humans. Remission Induction. Terminology as Topic

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Rheumatol. 2004 Jan;31(1):1-4 [14705208.001]
  • [Cites] Rheumatology (Oxford). 2009 Sep;48(9):1092-7 [19561156.001]
  • [Cites] Arthritis Rheum. 1981 Oct;24(10):1308-15 [7306232.001]
  • [Cites] Br J Rheumatol. 1996 Nov;35(11):1101-5 [8948296.001]
  • [Cites] Nat Rev Rheumatol. 2010 Feb;6(2):68-70 [20125170.001]
  • [Cites] Autoimmun Rev. 2010 Jan;9(3):161-4 [19602456.001]
  • [Cites] Scand J Rheumatol. 2010;39(1):12-8 [20132065.001]
  • [Cites] J Rheumatol. 2010 Feb;37(2):285-90 [20080905.001]
  • [Cites] Rheumatology (Oxford). 2010 Apr;49(4):683-90 [20047979.001]
  • [Cites] Arthritis Res Ther. 2010;12(1):R3 [20055986.001]
  • [Cites] J Rheumatol. 2010 Jul;37(7):1444-53 [20516031.001]
  • [Cites] J Rheumatol. 2001 Feb;28(2):355-9 [11246676.001]
  • [Cites] Rheum Dis Clin North Am. 1997 Feb;23(1):195-212 [9031383.001]
  • [Cites] Ann Rheum Dis. 2005 Oct;64(10):1410-3 [15941836.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3554-62 [16255044.001]
  • [Cites] Clin Exp Rheumatol. 2005 Sep-Oct;23(5 Suppl 39):S100-8 [16273793.001]
  • [Cites] Semin Arthritis Rheum. 2005 Dec;35(3):185-96 [16325659.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-1-6 [17083755.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-14-21 [17083757.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-22-8 [17083758.001]
  • [Cites] Arthritis Rheum. 2006 Dec;54(12):3761-73 [17133543.001]
  • [Cites] Z Rheumatol. 2006 May;65(3):209-12, 214-6 [16670812.001]
  • [Cites] Ann Rheum Dis. 2007 Mar;66(3):358-63 [16935911.001]
  • [Cites] Arthritis Res Ther. 2007;9(4):R72 [17662115.001]
  • [Cites] South Med J. 2008 Mar;101(3):240-5 [18364651.001]
  • [Cites] Arthritis Rheum. 2008 Aug;58(8):2241-7 [18668546.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2642-51 [18759292.001]
  • [Cites] Arthritis Rheum. 2008 Sep 15;59(9):1241-8 [18759316.001]
  • [Cites] N Engl J Med. 1948 Jan 29;238(5):142-8 [18921122.001]
  • [Cites] Arthritis Rheum. 2008 Oct;58(10):2958-67 [18821687.001]
  • [Cites] Rheumatol Int. 2008 Dec;29(2):131-9 [18807254.001]
  • [Cites] BMC Musculoskelet Disord. 2009;10:41 [19389230.001]
  • [Cites] Ann Rheum Dis. 2009 Jun;68(6):914-21 [18662933.001]
  • [Cites] Arthritis Rheum. 2009 May 15;61(5):704-10 [19405006.001]
  • [Cites] J Rheumatol. 2009 May;36(5):930-3 [19332634.001]
  • [Cites] Arthritis Rheum. 2009 May;60(5):1242-9 [19404938.001]
  • [Cites] J Rheumatol. 2009 Jul;36(7):1532-5 [19487265.001]
  • [Cites] Arthritis Rheum. 2009 Aug;60(8):2262-71 [19644846.001]
  • [Cites] Arthritis Rheum. 2004 Jan;50(1):36-42 [14730597.001]
  • (PMID = 20697983.001).
  • [ISSN] 1534-6307
  • [Journal-full-title] Current rheumatology reports
  • [ISO-abbreviation] Curr Rheumatol Rep
  • [Language] eng
  • [Grant] United States / NIAMS NIH HHS / AR / K23 AR057818
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2927687
  •  go-up   go-down


8. Reinfjell T, Lofstad GE, Nordahl HM, Vikan A, Diseth TH: Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning. Eur J Cancer Care (Engl); 2009 Jul;18(4):364-70
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioning.
  • Children in remission from acute lymphoblastic leukaemia: mental health, psychosocial adjustment and parental functioningThe objective of this study is to assess the mental health and psychosocial adjustment of children in remission from acute lymphoblastic leukaemia (ALL), and parental functioning compared to healthy controls.
  • Children in remission from ALL showed on average significantly more problems regarding mental health and psychosocial adjustment, as reported by their parents, compared with healthy controls.
  • Adequate rehabilitation and follow-up programmes should be implemented for children in remission from ALL.
  • [MeSH-major] Adaptation, Psychological. Mental Disorders / epidemiology. Parents / psychology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology
  • [MeSH-minor] Adolescent. Adult. Anxiety / epidemiology. Child. Cross-Sectional Studies. Depression / epidemiology. Female. Health Status. Humans. Male. Middle Aged. Norway. Remission Induction. Surveys and Questionnaires

  • MedlinePlus Health Information. consumer health - Child Mental Health.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19473372.001).
  • [ISSN] 1365-2354
  • [Journal-full-title] European journal of cancer care
  • [ISO-abbreviation] Eur J Cancer Care (Engl)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


9. Reinfjell T, Lofstad GE, Veenstra M, Vikan A, Diseth TH: Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia. Acta Paediatr; 2007 Sep;96(9):1280-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health-related quality of life and intellectual functioning in children in remission from acute lymphoblastic leukaemia.
  • AIM: To evaluate the health-related quality of life (HRQOL) and intellectual functioning of children in remission from acute lymphoblastic leukaemia (ALL).
  • Follow-up programs that target the psychosocial health of children in remission from ALL should be implemented.
  • [MeSH-major] Cognition / physiology. Health Status. Precursor Cell Lymphoblastic Leukemia-Lymphoma / psychology. Quality of Life / psychology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Male. Neuropsychological Tests. Remission Induction. Surveys and Questionnaires

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Paediatr. 2007 Sep;96(9):1265-8 [17718778.001]
  • (PMID = 17590194.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Norway
  •  go-up   go-down


10. Ortmann J, Schiffl H, Lang SM: [Partial clinical remission of chronic IgA nephropathy with therapy of tuberculosis]. Dtsch Med Wochenschr; 2010 Jun;135(24):1228-31
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Partial clinical remission of chronic IgA nephropathy with therapy of tuberculosis].
  • [Transliterated title] Partielle klinische Remission einer chronischen IgA-Nephropathie unter antituberkulotischer Therapie.
  • INVESTIGATIONS: The diagnosis of the underlying etiology of the pleural effusions was difficult in spite of a thorough diagnostic work-up.
  • CONCLUSIONS: This report of a partial remission of IgA nephropathy by treatment of pleural tuberculosis supports the hypothesis that there may be a causal relationship between mycobacterial infections and IgA nephropathy.
  • [MeSH-minor] Adult. Biopsy. Drug Therapy, Combination. Humans. Kidney / pathology. Male. Pleural Effusion / diagnosis. Pleural Effusion / drug therapy. Pleural Effusion / etiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Tuberculosis.
  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20533156.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antitubercular Agents
  •  go-up   go-down


11. Ostendorf B, Scherer A, Kellner H, Backhaus M: [Project REMISSION(PLUS): clinical and radiological remission : new treatment goals in the management of rheumatoid arthritis]. Z Rheumatol; 2008 Dec;67(8):707-10, 712-5
MedlinePlus Health Information. consumer health - Ultrasound.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Project REMISSION(PLUS): clinical and radiological remission : new treatment goals in the management of rheumatoid arthritis].
  • [Transliterated title] Projekt REMISSION(PLUS): klinische und radiologische Remission : Neue Therapieziele in der Behandlung der rheumatoiden Arthritis.
  • The REMISSION(PLUS) initiative aspire to integrate modern imaging technologies as standard methods in the care and management of RA patients.
  • The main areas on which this initiative will be focusing are the conceptualization and implementation of educational programs and training seminars on sonography and MRI, the development and establishment of case report forms for standardized documentation of findings, and the systematic monitoring of patients on treatment, with the aim of producing very precise documentation of structural change processes in RA and also, if possible, to document radiological remission or even progression.
  • The REMISSION(PLUS) project also includes the setting up of specialized centers of excellence, which will network to support the implementation and access to the various imaging procedures at hospitals, rheumatology clinics and rheumatology practices nationwide.
  • [MeSH-major] Arthritis, Rheumatoid / diagnosis. Arthrography. Magnetic Resonance Imaging. Patient Care Team. Ultrasonography
  • [MeSH-minor] Documentation. Follow-Up Studies. Humans. Joints / pathology. Remission Induction. Synovial Membrane / pathology. Synovitis / diagnosis. Synovitis / therapy


12. Al-Ali HK, Wittekind C, Niederwieser D: [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab]. Dtsch Med Wochenschr; 2007 Aug;132(33):1688-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
  • [Transliterated title] Komplette Remission eines rezidivierenden Hodgkin-Lymphoms vom Mischzelligen Typ nach Rituximab-Therapie.
  • Complete remission (CR) was achieved after six cycles of doxorubicin-bleomycin-vinblastin-dacarbazine (ABVD) and cyclophosphamid-vincristine-procarbazine-prednison (COPP) regimens.
  • Histology confirmed the initial diagnosis.
  • A partial remission was induced with two further DEXA-BEAM cycles (dexamethasone, BCNU [1,3-bis(2-chloroethyl)-1-nitrosourea], ectoposide, ara-C, melphalan).
  • A complete remission was achieved 2 months later.
  • A second treatment with rituximab yielded another complete remission which was maintained for 20 months.
  • In our patient the safety and efficacy of rituximab in relapsed CD20-positive classical HD of an MC type was demonstrated to achieve long-lasting remission.
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / therapeutic use. Carmustine / therapeutic use. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Dacarbazine / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Humans. Lymph Nodes / pathology. Male. Melphalan / therapeutic use. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prednisone / therapeutic use. Procarbazine / therapeutic use. Remission Induction / methods. Rituximab. Treatment Outcome. Vinblastine / therapeutic use. Vincristine / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17713864.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 04079A1RDZ / Cytarabine; 11056-06-7 / Bleomycin; 35S93Y190K / Procarbazine; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; VB0R961HZT / Prednisone; ABVD protocol; COPP protocol; Dexa-BEAM protocol
  •  go-up   go-down


13. Wolf P: [Epilepsy as a dynamic condition: facilitation and inhibition, establishment and remission]. Ugeskr Laeger; 2005 Oct 10;167(41):3865-7
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epilepsy as a dynamic condition: facilitation and inhibition, establishment and remission].
  • [Transliterated title] Epilepsi som dynamisk tilstand: fremme og haemning af anfald, etablering og remission.
  • Some of these are known, and their action can best be observed at onset, when seizure repetition is established or prevented, and at remission, when the decline of the antiepileptic drug therapeutic threshold reflects a fall in the propensity to seizures.
  • [MeSH-minor] Anticonvulsants / therapeutic use. Humans. Models, Biological. Remission, Spontaneous

  • Genetic Alliance. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16221424.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


14. Petruskevicius I, Bukh A, Mertz H, Johnsen HE: [Complete remission after Rituximab treatment in refractory hairy cell leukemia]. Ugeskr Laeger; 2008 Jun 23;170(26-32):2350
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Complete remission after Rituximab treatment in refractory hairy cell leukemia].
  • [Transliterated title] Komplet remission efter rituximabbehandling ved refraktaer hårcelleleukaemi.
  • A 40 year-old man with hairy cell leukemia (HCL) was treated with Cladribin, but achieved only partial response (PR).
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Leukemia, Hairy Cell / drug therapy
  • [MeSH-minor] Adult. Antibodies, Monoclonal, Murine-Derived. Humans. Male. Neoplasm Recurrence, Local. Remission Induction. Rituximab

  • Genetic Alliance. consumer health - Hairy Cell Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18570771.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


15. Pories W: [Type II diabetes. Permanent remission by surgery of the foregut]. Chirurg; 2009 May;80(5):416, 418-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Type II diabetes. Permanent remission by surgery of the foregut].
  • [Transliterated title] Typ-II-Diabetes : Dauerhafte Remission durch Chirurgie des Foregut.
  • Bariatric surgery offers a safe and effective treatment of type II diabetes for morbidly obese persons with complete and permanent remission as well as a clear reduction in mortality.

  • Genetic Alliance. consumer health - Diabetes.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obes Surg. 2009 Mar;19(3):307-12 [18987919.001]
  • [Cites] Obes Surg. 2007 Oct;17(10):1332-9 [18098400.001]
  • [Cites] Ann Surg. 2006 Nov;244(5):741-9 [17060767.001]
  • [Cites] Surg Obes Relat Dis. 2006 Sep-Oct;2(5):497-503; discussion 503 [17015199.001]
  • [Cites] Ann Surg. 1998 May;227(5):637-43; discussion 643-4 [9605655.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1593-602 [17035653.001]
  • [Cites] Ann Surg. 1987 Sep;206(3):316-23 [3632094.001]
  • [Cites] Surg Obes Relat Dis. 2007 Mar-Apr;3(2):195-7 [17386401.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Dec;93(12):4656-63 [18765510.001]
  • [Cites] Ann Surg. 2003 Oct;238(4):467-84; discussion 84-5 [14530719.001]
  • [Cites] Ann Surg. 1995 Sep;222(3):339-50; discussion 350-2 [7677463.001]
  • [Cites] J Gastrointest Surg. 1997 May-Jun;1(3):213-20; discussion 220 [9834350.001]
  • [Cites] Obes Res. 1996 May;4(3):316-9 [8732969.001]
  • [Cites] JAMA. 2008 Jan 23;299(3):316-23 [18212316.001]
  • [Cites] N Engl J Med. 2007 Aug 23;357(8):741-52 [17715408.001]
  • [Cites] N Engl J Med. 2007 Aug 23;357(8):753-61 [17715409.001]
  • [Cites] J Clin Endocrinol Metab. 2008 Jul;93(7):2479-85 [18430778.001]
  • (PMID = 19440748.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Incretins
  • [Number-of-references] 22
  •  go-up   go-down


16. Haas A, Lobeck H, Hummel M, Maschmeyer G: [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma]. Dtsch Med Wochenschr; 2006 Oct 27;131(43):2386-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma].
  • [Transliterated title] Anhaltende Remission nach Immuntherapie bei zuvor refraktärem peripherem T-Non-Hodgkin-Lymphom.
  • The follow up CT-scans one year after treatment showed a stable remission.
  • CONCLUSION: In T-NHL with primary non-response it is especially difficult to induce a stable remission.
  • Despite a course which was complicated by infections and a failing response to increased chemotherapy a remission was achieved in this patient with a monotherapy of alemtuzumab for eight weeks without complications, followed by radiotherapy.
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Etoposide / therapeutic use. Female. Germany. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. L-Lactate Dehydrogenase / blood. Middle Aged. Neoplasm Staging. Prednisolone / therapeutic use. Radiotherapy, Adjuvant. Recombinant Proteins. Remission Induction. Tomography, X-Ray Computed. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054053.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3A189DH42V / alemtuzumab; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 1.1.1.27 / L-Lactate Dehydrogenase; CHOEP protocol
  •  go-up   go-down


17. Aigner N, Petje G, Schneider W, Meizer R, Wlk M, Kotsaris S, Knahr K, Landsiedl F: Bone marrow edema syndrome of the femoral head : Treatment with the prostacyclin analogue iloprost vs. core decompression: An MRI-controlled study. Wien Klin Wochenschr; 2005 Feb;117(4):130-135

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Knochenmarködemsyndrom des Hüftkopfes : Behandlung mit dem Prostazyklinanalogon Iloprost im Vergleich zur Hüftkopfbohrung: Eine MRT-kontrollierte Studie.
  • MRI controls showed complete remission in all hips.
  • MRI controls showed complete remission of BMES in 14 hips, residual focal bone marrow edema in four hips and a small osteonecrotic area in two hips.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28108806.001).
  • [ISSN] 1613-7671
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Austria
  • [Keywords] NOTNLM ; Avascular necrosis / Bone marrow edema syndrome / Core decompression / Iloprost / Vasoactive drug
  •  go-up   go-down


18. Mantadakis E, Anagnostatou N, Danilatou V, Markaki EA, Spanaki AM, Briassoulis G, Kalmanti M: Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review. J Pediatr Hematol Oncol; 2005 Oct;27(10):551-3
MedlinePlus Health Information. consumer health - Chickenpox.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant hepatitis due to varicella zoster virus in a girl with acute lymphoblastic leukemia in remission: report of a case and review.
  • The authors describe a 4-year-old girl with acute lymphoblastic leukemia in remission who developed fulminant hepatic failure due to varicella-zoster virus (VZV).
  • [MeSH-major] Chickenpox / virology. Hepatitis, Viral, Human / virology. Herpesvirus 3, Human / isolation & purification. Liver Failure, Acute / virology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child, Preschool. Fatal Outcome. Female. Humans. Immunocompromised Host. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Hepatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16217259.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Wolter A, Preuss U, Krischke N, Wong JW, Langosch JM, Zimmermann J: [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study]. Fortschr Neurol Psychiatr; 2010 Aug;78(8):468-74
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Recovery and remission in schizophrenia. Results from a naturalistic 2-year follow-up inpatient study].
  • [Transliterated title] Recovery und Remission bei Schizophrenie. Ergebnisse einer naturalistischen 2-Jahres-Katamnesestudie ehemals stationärer Patienten.
  • INTRODUCTION: Remission in schizophrenia is defined as a period of at least 6 months in which symptom reduction occurs.
  • Criteria of remission for each domain were assessed using the BPRS (brief psychiatric rating scale, symptomatic remission), GAF (global assessment of functioning, functional remission) and the SWN-K (subjective well-being under neuroleptics, remission of subjective well-being).
  • Approximately one-third of the individuals had remission with a stable quality of life.
  • CONCLUSION: Compared to previous studies, the rates of remission and recovery in the current sample were quite low.
  • [MeSH-minor] Adult. Age of Onset. Antipsychotic Agents / therapeutic use. Female. Follow-Up Studies. Humans. Inpatients. Longitudinal Studies. Male. Middle Aged. Prospective Studies. Psychiatric Status Rating Scales. Quality of Life. Recovery of Function. Remission, Spontaneous

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) Georg Thieme Verlag KG Stuttgart--New York.
  • (PMID = 20694939.001).
  • [ISSN] 1439-3522
  • [Journal-full-title] Fortschritte der Neurologie-Psychiatrie
  • [ISO-abbreviation] Fortschr Neurol Psychiatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


20. Foghsgaard S, Kjaergård HK: [Total remission of hemiparesis after operation in acute aortic dissection]. Ugeskr Laeger; 2008 May 5;170(19):1650-1
MedlinePlus Health Information. consumer health - Aortic Aneurysm.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Total remission of hemiparesis after operation in acute aortic dissection].
  • [Transliterated title] Fuldstaendig remission af hemiparese efter operation for akut proksimal aortadissektion.
  • Cerebral ischaemia might not preclude operation in acute aortic dissection.
  • A 37-year-old male with an acute proximal aortic dissection (type A) and coma and hemiparesis caused by involvement of the arch vessels and secondary brain malperfusion underwent emergency surgical repair with replacement of the ascending aorta in profound circulatory arrest.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489876.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


21. Bannowsky A, Wefer B, Naumann M, Hamann M, Hautmann S, Jünemann KP: ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"]. Urologe A; 2005 Aug;44(8):915-7
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ["Second line" polychemotherapy in metastatic urothelial cancer of the renal pelvis. Persisting partial remission by 18 treatment cycles of gemcitabine/paclitaxel after 24 treatment cycles gemcitabine/cisplatin "stable disease"].
  • [Transliterated title] "Second-line-Polychemotherapie" beim metastasierten Urothelkarzinom des Nierenbeckens. Andauernde partielle Remission nach 18 Kursen Gemcitabin/Paclitaxel trotz 24 Kursen Gemcitabin/Cisplatin im "stable disease".
  • We report an interesting case of a 59-year-old man suffering from urothelial cancer of the renal pelvis with pulmonary, lymphogenous, and bone metastases who had an unexpected response to "second-line" chemotherapy with only 2 treatment cycles of gemcitabine/paclitaxel (partial remission) after 24 treatment cycles of gemcitabine/cisplatin in "stable disease" with progression between the therapeutic intervals.
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Disease Progression. Drug Administration Schedule. Drug Resistance, Neoplasm. Humans. Male. Middle Aged. Remission Induction. Retroperitoneal Neoplasms / diagnostic imaging. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / secondary. Tomography, X-Ray Computed


22. Yoruk A, Erguven M, Celiker E, Aki H, Timur C, Yuksel E, Ozkan H: Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass. Pediatr Hematol Oncol; 2008 Apr-May;25(3):181-6
Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass.
  • Spontaneous remission/regression of cancer is defined as partial or complete disappearance of malignant disease temporarily or permanently in the absence of medical treatment.
  • This event is named as spontaneous regression for solid tumors and spontaneous remission for leukemia.
  • The authors report the case of a girl aged 4 years and 3 months, who presented with mediastinal mass and leukemic findings in the bone marrow both of which reappeared after spontaneous regression and remission, respectively.
  • [MeSH-major] Mediastinal Neoplasms. Neoplasm Regression, Spontaneous. Precursor Cell Lymphoblastic Leukemia-Lymphoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432500.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


23. Boguth K, Schenk L: [New-onset urinary incontinence in the first six month after admission into a nursing home: prevalence, incidence and remission, risk and protective factors]. Z Gerontol Geriatr; 2008 Aug;41(4):274-82
MedlinePlus Health Information. consumer health - Urinary Incontinence.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [New-onset urinary incontinence in the first six month after admission into a nursing home: prevalence, incidence and remission, risk and protective factors].
  • [Transliterated title] Neuerkrankung an Harninkontinenz in den ersten sechs Monaten nach dem Heimeintritt: Prävalenz, Inzidenz und Remission, Risiko und Schutzfaktoren.

  • Genetic Alliance. consumer health - Incontinence.
  • MedlinePlus Health Information. consumer health - Nursing Homes.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677627.001).
  • [ISSN] 0948-6704
  • [Journal-full-title] Zeitschrift für Gerontologie und Geriatrie
  • [ISO-abbreviation] Z Gerontol Geriatr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


24. Möller HJ, Bauer M, Fritze J, Haen E, Laux G, Müller WE, Rüther E: [Selective serotonin and noradrenaline reuptake inhibitors: a step forward in the treatment of depression?]. MMW Fortschr Med; 2005 Jan 20;147(3):43-5
MedlinePlus Health Information. consumer health - Anxiety.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Medikamentöse Behandlung von Depressionen und Angststörungen. Dem Therapieziel Remission wieder ein Schritt näher.
  • Nevertheless, only some of the patients experience a remission of their depressive symptoms.
  • [MeSH-major] Antidepressive Agents / therapeutic use. Anxiety Disorders / drug therapy. Depressive Disorder / drug therapy. Serotonin Uptake Inhibitors / therapeutic use. Symporters / antagonists & inhibitors

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Antidepressants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15727113.001).
  • [ISSN] 1438-3276
  • [Journal-full-title] MMW Fortschritte der Medizin
  • [ISO-abbreviation] MMW Fortschr Med
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antidepressive Agents; 0 / Drug Combinations; 0 / Norepinephrine Plasma Membrane Transport Proteins; 0 / SLC6A2 protein, human; 0 / Serotonin Uptake Inhibitors; 0 / Symporters
  •  go-up   go-down


25. Bertozzi S, Londero AP, Fruscalzo A, Marchesoni D, Lellé RJ: [Paget disease of the vulva: resolution after local treatment with imiquimod--report of a case and review of the literature]. Gynakol Geburtshilfliche Rundsch; 2009;49(4):326-30
Hazardous Substances Data Bank. Imiquimod .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Morbus Paget der Vulva: Remission durch Lokalbehandlung mit Imiquimod--Fallbericht und Literaturübersicht.
  • Paget disease is a rare disorder of the skin of the vulva, comprising less than 1% of vulvar neoplasms.
  • Within 8 weeks, complete clinical remission was achieved.

  • Genetic Alliance. consumer health - Paget Disease.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530949.001).
  • [ISSN] 1423-0011
  • [Journal-full-title] Gynäkologisch-geburtshilfliche Rundschau
  • [ISO-abbreviation] Gynakol Geburtshilfliche Rundsch
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Aminoquinolines; 0 / Antineoplastic Agents; 99011-02-6 / imiquimod
  •  go-up   go-down


26. Marjanovic G, Winkler K, Schewe T, Küsters S, Hopt UT, Kulemann B, Karcz WK: [Metabolic surgery and remission of type 2 diabetes]. Dtsch Med Wochenschr; 2010 May;135(20):1020-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metabolic surgery and remission of type 2 diabetes].
  • [Transliterated title] Metabolische Chirurgie und Remission des Diabetes mellitus Typ 2.

  • Genetic Alliance. consumer health - Diabetes.
  • Genetic Alliance. consumer health - Diabetes, Type 2.
  • MedlinePlus Health Information. consumer health - Diabetes Type 2.
  • MedlinePlus Health Information. consumer health - Weight Loss Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart * New York.
  • (PMID = 20461659.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 48
  •  go-up   go-down


27. Steinherz PG, Meyers PA, Steinherz LJ, Jeha S: Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia. J Pediatr Hematol Oncol; 2007 Sep;29(9):656-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.
  • Clofarabine is a new nucleoside analog that has demonstrated clinical benefit in phase I-II studies, and is currently being studied in children and adults with leukemias and has been approved for the treatment of children with relapsed or refractory acute lymphocytic leukemia.
  • We report the experience of three adolescents, two with acute lymphocytic leukemia in 3rd relapse and one with relapsed/refractory acute myeloid leukemia, who achieved complete remission with clofarabine.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia, Myeloid / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Acute Disease. Adolescent. Female. Humans. Male. Recurrence. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17805046.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Arabinonucleosides; 762RDY0Y2H / clofarabine
  •  go-up   go-down


28. Isaacs KL: How rapidly should remission be achieved? Dig Dis; 2010;28(3):548-55
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How rapidly should remission be achieved?
  • The major goal of therapy in inflammatory bowel disease is to induce remission.
  • Remission has multiple definitions - clinical remission, where the patient's symptoms have remitted, and endoscopic remission, in which there has been complete mucosal healing.
  • Mucosal healing is a harder endpoint of remission but may be more difficult to achieve.
  • Ideally we would like to see remission as quickly as possible to improve patient quality of life.
  • The time to remission varies between different therapeutic approaches.
  • Steroids tend to have a rapid clinical effect with remission seen in some patients as early as two weeks.
  • In early anti-TNF trials, a single dose of infliximab lead to 27% remission at two weeks compared to 4% of placebo patients.
  • Adalimumab and certolizumab have similar reports of early induction of remission.
  • Mesalamine in Crohn's disease has inconsistent and delayed remission rates, whereas in ulcerative colitis, response and remission rates are more consistent in the three-week time frame.
  • Azathioprine and 6-mercaptopurine have delayed onset of action but may induce remission as early as six weeks if dosing is optimized.
  • In this presentation induction of clinical remission and mucosal healing in Crohn's disease and ulcerative colitis will be discussed.
  • The impact of early remission on disease course will also be reviewed.
  • [MeSH-minor] Humans. Intestinal Mucosa / pathology. Remission Induction. Wound Healing

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20926885.001).
  • [ISSN] 1421-9875
  • [Journal-full-title] Digestive diseases (Basel, Switzerland)
  • [ISO-abbreviation] Dig Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


29. Mokrzycka M, Pawlik A, Kałdońska M, Millo B: Assessment of liver function in children with acute lymphoblastic leukemia in remission. Ann Acad Med Stetin; 2006;52(3):61-5; discussion 65
Hazardous Substances Data Bank. LIDOCAINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessment of liver function in children with acute lymphoblastic leukemia in remission.
  • PURPOSE: Acute lymphoblastic leukemia (ALL) is the most common malignant neoplasm in children.
  • MATERIAL AND METHODS: We enrolled 17 children and young adults with ALL in remission.
  • Mean remission time was 61 +/- 30 months.
  • [MeSH-major] Liver Function Tests. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / physiopathology
  • [MeSH-minor] Adolescent. Adult. Area Under Curve. Child. Diagnosis, Differential. Female. Half-Life. Hepatitis, Chronic / complications. Hepatitis, Chronic / diagnosis. Humans. Lidocaine / analogs & derivatives. Lidocaine / pharmacokinetics. Liver / metabolism. Male. Reference Values. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Liver Function Tests.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17385349.001).
  • [ISSN] 1427-440X
  • [Journal-full-title] Annales Academiae Medicae Stetinensis
  • [ISO-abbreviation] Ann Acad Med Stetin
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 7728-40-7 / monoethylglycinexylidide; 98PI200987 / Lidocaine
  •  go-up   go-down


30. Hurtado-Sarrió M, Duch-Samper A, Taboada-Esteve J, Martínez-Dominguez JA, Senent-Peris ML, Menezo-Rozalén JL: Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib. Am J Ophthalmol; 2005 Apr;139(4):723-4
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anterior chamber infiltration in a patient with Ph+ acute lymphoblastic leukemia in remission with imatinib.
  • PURPOSE: Anterior chamber involvement is unusual in patients with acute lymphoblastic leukemia (ALL) and has never been described in the setting of Ph+ (Philadelphia chromosome-positive) ALL.
  • METHODS: A 55-year-old woman with Ph+ ALL in complete remission with imatinib and presenting unilateral anterior uveitis at initial examination was clinically evaluated.
  • RESULTS: Although there was no evidence of leukemia in the blood or bone marrow samples, aqueous fluid cytology identified Ph+ positive lymphoblastic leukemic cells.
  • [MeSH-major] Anterior Chamber / pathology. Antineoplastic Agents / therapeutic use. Eye Neoplasms / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy. Leukemic Infiltration / pathology. Piperazines / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pyrimidines / therapeutic use
  • [MeSH-minor] Aqueous Humor / cytology. Benzamides. Female. Humans. Imatinib Mesylate. In Situ Hybridization, Fluorescence. Middle Aged. Philadelphia Chromosome. Remission Induction. Uveitis, Anterior / diagnosis


31. van Os J, Burns T, Cavallaro R, Leucht S, Peuskens J, Helldin L, Bernardo M, Arango C, Fleischhacker W, Lachaux B, Kane JM: Standardized remission criteria in schizophrenia. Acta Psychiatr Scand; 2006 Feb;113(2):91-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Standardized remission criteria in schizophrenia.
  • OBJECTIVE: Recent work has focussed on schizophrenia as a 'deficit' state but little attention has been paid to defining illness plasticity in terms of symptomatic remission.
  • METHOD: A qualitative review of a recently proposed concept of remission [N.C.
  • RESULTS: The proposed definition of remission is conceptually viable, and can be easily implemented in clinical trials and clinical practice.
  • The availability of validated outcome measures based on remission will enhance the conduct and reporting of clinical investigations, and could facilitate the design and interpretation of new studies on cognition and functional outcomes.
  • While useful as a concept, it is important to consider that remission is distinct from recovery.
  • CONCLUSION: The introduction of standardized remission criteria may offer significant opportunities for clinical practice, health services research and clinical trials.
  • [MeSH-minor] Chronic Disease. Clinical Trials as Topic / standards. Follow-Up Studies. Humans. Remission Induction / methods

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Acta Psychiatr Scand. 2007 Feb;115(2):163-4; author reply 164 [17244184.001]
  • [CommentIn] Acta Psychiatr Scand. 2006 Feb;113(2):81 [16423157.001]
  • (PMID = 16423159.001).
  • [ISSN] 0001-690X
  • [Journal-full-title] Acta psychiatrica Scandinavica
  • [ISO-abbreviation] Acta Psychiatr Scand
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 13
  •  go-up   go-down


32. van Os J, Kahn R: [Remission criteria in schizophrenia]. Tijdschr Psychiatr; 2007;49(1):21-6
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Remission criteria in schizophrenia].
  • [Transliterated title] Remissiecriteria voor de diagnose schizofrenie.
  • AIM: An internationally accepted standard definition of symptomatic remission.
  • METHOD: Two international panels of experts have wrestled with the problem of whether or how symptomatic remission in persons diagnosed with schizophrenia can be defined.
  • Acceptance of the remission concept can raise expectations about treatment outcome to a higher level than is possible when a patient is merely defined as being 'stable', can improve the quality of treatment documentation and facilitate the dialogue concerning treatment expectations.
  • The availability of validated outcome measures based on remission should enhance the reporting and the comparability of clinical research and should facilitate the design and interpretation of new research into the relation between symptomatic remission and functional outcomes.
  • CONCLUSION: The introduction of standard remission criteria can create many opportunities for clinical practice, clinical research and cumulative records of results; at the same time it can facilitate a dialogue with patients and help to clarify the diagnosis of schizophrenia.
  • [MeSH-major] Outcome Assessment (Health Care) / standards. Remission Induction. Schizophrenia. Schizophrenic Psychology
  • [MeSH-minor] Diagnosis, Differential. Humans. Treatment Outcome

  • Genetic Alliance. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17225202.001).
  • [ISSN] 0303-7339
  • [Journal-full-title] Tijdschrift voor psychiatrie
  • [ISO-abbreviation] Tijdschr Psychiatr
  • [Language] dut
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Netherlands
  • [Number-of-references] 15
  •  go-up   go-down


33. de Vlam K, Lories RJ: Remission in psoriatic arthritis. Curr Rheumatol Rep; 2008 Aug;10(4):297-302
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in psoriatic arthritis.
  • PsA has a low likelihood of clinical remission and cure.
  • Remission may now be an attainable outcome in the treatment paradigm.
  • At this time, specific tools to define PsA remission are not available.
  • New assessments to define remission must be developed and incorporated into clinical trials and longitudinal registries.
  • [MeSH-minor] Female. Humans. Male. Remission Induction


34. van Os J, Drukker M, à Campo J, Meijer J, Bak M, Delespaul P: Validation of remission criteria for schizophrenia. Am J Psychiatry; 2006 Nov;163(11):2000-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Validation of remission criteria for schizophrenia.
  • OBJECTIVE: Remission criteria for schizophrenia have been proposed, consisting of a time criterion and a symptomatic remission criterion.
  • With longitudinal data of a representative patient group (N=317; median follow-up: 1,132 days), validity of the symptomatic remission criterion was investigated.
  • METHOD: In a group of 145 patients meeting the symptomatic remission criterion at baseline and a group of 172 patients not meeting it at baseline, change over time in remission status was examined in relation to change in various functional outcomes.
  • RESULTS: In both groups, change over time with the symptomatic remission criterion was associated with substantial changes in unmet needs, Global Assessment of Functioning scale scores, satisfaction with services and, to a lesser extent, quality of life.
  • Changing the symptomatic remission criterion to include depression and suicidality did not affect the results.
  • CONCLUSIONS: The proposed symptomatic remission criterion has clinical validity and represents the right balance between parsimony and inclusiveness.
  • [MeSH-minor] Depressive Disorder / psychology. Follow-Up Studies. Humans. Longitudinal Studies. Patient Satisfaction. Quality of Life. Reproducibility of Results. Sensitivity and Specificity. Suicide / psychology. Time Factors

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17074953.001).
  • [ISSN] 0002-953X
  • [Journal-full-title] The American journal of psychiatry
  • [ISO-abbreviation] Am J Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Wang H, Li D, Li JT, Wang XL, Hao LC: [Side effects of L-asparaginase during therapies for remission induction and maintenance in children with acute lymphocytic leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun;17(3):739-41

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Side effects of L-asparaginase during therapies for remission induction and maintenance in children with acute lymphocytic leukemia].
  • This study was purposed to investigate the possible side effects of L-asparaginase (L-ASP) in the treatment of patients with acute lymphoblastic leukemia (ALL) and to explore the correlation of these side effects at different therapeutic stages by means of retrospective analysis, so as to reduce the incidence of side effects and improve the safety of chemotherapy and the long-term survival of patients.
  • The probability and severity of side effects related to use of L-ASP in 38 cases of ALL during remission induction therapy (VDLDex regimen) and 40 cases of ALL during maintenance intensive therapy (VMLDex regimen) were compared.
  • The results showed that allergic response, diabetes and drug-induced liver disease happened more frequently during maintenance therapy than during remission induction therapy, while defibrination, abnormal hemagglutinin, acute pancreatitis, hypoproteinemia, gastrointestinal reaction and infectious shock were observed more during remission induction therapy than those at maintenance therapy.
  • In conclusion, the L-ASP showed some side effects especially for the patients during the remission induction therapy which should be paid enough attention.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19549398.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


36. Kavanaugh A, Fransen J: Defining remission in psoriatic arthritis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-83-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining remission in psoriatic arthritis.
  • In other conditions, such as rheumatoid arthritis, recent discussions have centered on how best to define "remission."
  • For patients with PsA, the heterogeneity among disease manifestations as well as the need to validate outcome measures make definition of remission challenging.
  • In this paper we present a number of key principles and considerations critical to laying the groundwork for defining remission in PsA.
  • [MeSH-minor] Finger Joint / immunology. Humans. Inflammation / drug therapy. Practice Guidelines as Topic. Reference Values. Remission Induction. Toe Joint / immunology


37. Zochling J, Braun J: Remission in ankylosing spondylitis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-88-92
MedlinePlus Health Information. consumer health - Ankylosing Spondylitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in ankylosing spondylitis.
  • Remission is a major goal of medical therapy in chronic disease.
  • The concept of disease remission in AS has not received much attention in the current literature.
  • There exists one set of partial remission criteria formally developed by the ASsessments in Ankylosing Spondylitis (ASAS) working group on the basis of clinical trials with nonsteroidal anti-inflammatory drugs for use in clinical trials.
  • As more effective therapies become available for AS, disease remission is increasingly regarded as an appropriate therapeutic goal that may then be translated into modification of progressive structural damage.
  • There is a need to further define and evaluate current proposals concerning remission in AS.
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Clinical Trials as Topic. Humans. Practice Guidelines as Topic. Remission Induction

  • Genetic Alliance. consumer health - Ankylosing Spondylitis.
  • Genetic Alliance. consumer health - Spondylitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083769.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 40
  •  go-up   go-down


38. Sokka T, Mäkinen H: Remission makes its way to rheumatology. Arthritis Res Ther; 2010;12(4):129
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission makes its way to rheumatology.
  • Remission was a rare event, even in the most advanced rheumatology clinics, until recent times.
  • However, in the early 1990s, it was chosen as the treatment goal and the primary outcome measure for the Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial, which can be considered the beginning of remission's way to rheumatology.
  • In addition to remission in patients with rheumatoid arthritis, remission in patients with psoriatic arthritis is now being studied, although remission criteria for psoriatic arthritis have yet to be defined.
  • [MeSH-minor] Humans. Remission Induction

  • MedlinePlus Health Information. consumer health - Psoriatic Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arthritis Rheum. 1981 Oct;24(10):1308-15 [7306232.001]
  • [Cites] Arthritis Res Ther. 2010;12(3):R94 [20482783.001]
  • [Cites] Lancet. 1999 May 8;353(9164):1568-73 [10334255.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1009-19 [15818706.001]
  • [Cites] J Rheumatol. 2005 May;32(5):796-800 [15868611.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3381-90 [16258899.001]
  • [Cites] Clin Exp Rheumatol. 2006 Nov-Dec;24(6 Suppl 43):S-22-8 [17083758.001]
  • [Cites] J Rheumatol. 2007 Feb;34(2):316-21 [17183623.001]
  • [Cites] Rheumatology (Oxford). 2007 Jun;46(6):1020-3 [17405761.001]
  • [Cites] Ann Rheum Dis. 2008 Jun;67(6):815-22 [17878209.001]
  • [Cites] Curr Rheumatol Rep. 2008 Aug;10(4):297-302 [18662510.001]
  • [Cites] Arthritis Rheum. 2008 Sep;58(9):2642-51 [18759292.001]
  • [Cites] Ann Rheum Dis. 2008 Dec;67(12):1710-5 [18218667.001]
  • [Cites] Ann Rheum Dis. 2010 Apr;69(4):631-7 [20215140.001]
  • [Cites] Arthritis Rheum. 1984 Aug;27(8):864-72 [6431998.001]
  • (PMID = 20642867.001).
  • [ISSN] 1478-6362
  • [Journal-full-title] Arthritis research & therapy
  • [ISO-abbreviation] Arthritis Res. Ther.
  • [Language] eng
  • [Publication-type] Editorial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Other-IDs] NLM/ PMC2945015
  •  go-up   go-down


39. Mitsuishi T, Iida K, Kawana S: Papulonecrotic tuberculid with spontaneous remission. J Dermatol; 2006 Feb;33(2):112-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Papulonecrotic tuberculid with spontaneous remission.
  • We describe a 62-year-old Japanese woman who had skin lesions involving her extremities, chest and back that showed spontaneous remission.
  • [MeSH-minor] Biopsy, Needle. Female. Humans. Immunohistochemistry. Japan. Middle Aged. Rare Diseases. Remission, Spontaneous. Risk Assessment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16556278.001).
  • [ISSN] 0385-2407
  • [Journal-full-title] The Journal of dermatology
  • [ISO-abbreviation] J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


40. Masuko M, Furukawa T, Yersser O, Narita M, Toba K, Koike T, Aizawa Y: Persistence of various chromosomal aberrations in recipient cells during complete remission after bone marrow transplantation followed by graft rejection. Leuk Res; 2005 Sep;29(9):1083-7
MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistence of various chromosomal aberrations in recipient cells during complete remission after bone marrow transplantation followed by graft rejection.
  • A 16-year-old boy in a second remission of acute lymphoblastic leukemia (ALL) had undergone transplantation of bone marrow from an unrelated donor.
  • Although the donor marrow was rejected, hematopoiesis by the recipient himself recovered and he has remained in complete remission for more than 8 years after stem cell transplantation (SCT).
  • Although complete remission was maintained, various chromosomal aberrations were detected in marrow cells, and in peripheral blood cells under phytohemagglutinin stimulation over 8 years.
  • This persistence of various chromosomal aberrations and a stable clone without evolution to myelodysplastic syndrome or leukemia support the multi step theory of leukemogenesis.
  • [MeSH-major] Bone Marrow Transplantation. Chromosome Aberrations. Graft Rejection. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16038736.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Alshayeb H, Wall BM: Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report. Cases J; 2009;2:7201

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis: rare case of long term remission with chemotherapy: a case report.
  • CASE PRESENTATION: The current report describes a patient who presented with the abrupt onset of hypertension, mixed nephritic/nephrotic syndrome and acute renal failure.
  • Bone marrow biopsy performed in the evaluation of periaortic lymphadenopathy, hepatosplenomegaly, and thrombocytopenia confirmed the diagnosis of low grade B-cell non-Hodgkin's lymphoma.
  • During eleven years of follow up, membranoproliferative glomerulonephritis has remained in remission, as confirmed by repeatedly negative urinalyses, normal blood pressure and absence of clinical signs and symptoms suggestive of nephritic/nephrotic syndrome.
  • CONCLUSION: Membranoproliferative glomerulonephritis has been known to be associated with both chronic lymphocytic leukemia and non-Hodgkin's lymphoma, particularly with B cell lymphocytic type non-Hodgkin's lymphoma.
  • This report presented a rare case of non-Hodgkin's lymphoma associated membranoproliferative glomerulonephritis, that continued to be in remission during eleven years of follow up after initial chemotherapy treatment of lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Kidney Int. 1992 Jul;42(1):127-35 [1635342.001]
  • [Cites] Am J Kidney Dis. 1991 Mar;17(3):247-57 [1996564.001]
  • [Cites] Kidney Int. 1987 Mar;31(3):781-9 [3106698.001]
  • [Cites] Am J Med. 1986 Jan;80(1):63-70 [3510541.001]
  • [Cites] Curr Opin Nephrol Hypertens. 2005 Jul;14(4):396-403 [15931011.001]
  • [Cites] Am J Nephrol. 1999;19(5):599-604 [10575191.001]
  • [Cites] Eur J Haematol. 2001 Sep;67(3):158-64 [11737248.001]
  • [Cites] Clin Nephrol. 2002 Apr;57(4):303-9 [12005247.001]
  • [Cites] Kidney Int. 2004 Jan;65(1):85-96 [14675039.001]
  • [Cites] Kidney Int. 1999 Jul;56(1):355-77 [10411717.001]
  • (PMID = 20181193.001).
  • [ISSN] 1757-1626
  • [Journal-full-title] Cases journal
  • [ISO-abbreviation] Cases J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2827065
  •  go-up   go-down


42. Ma MH, Scott IC, Kingsley GH, Scott DL: Remission in early rheumatoid arthritis. J Rheumatol; 2010 Jul;37(7):1444-53
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in early rheumatoid arthritis.
  • OBJECTIVE: We systematically reviewed remission as an outcome measure in observational studies and randomized controlled trials (RCT) in early rheumatoid arthritis (RA).
  • Our objectives were to identify its frequency using different criteria, to determine the influence of different treatment strategies on remission, and to review the effects of remission on radiological outcomes.
  • METHODS: Pubmed, Medline and Embase were searched using the following terms: Early Rheumatoid Arthritis or Early RA combined with Remission, Treatment, anti-Tumor Necrosis Factor (TNF) or Disease-modifying Antirheumatic Drugs (DMARD).
  • RESULTS: Seventeen observational studies (4762 patients) reported remission in 27% of patients, 17% by ACR criteria and 33% by DAS criteria.
  • Observational studies showed continuing radiological progression despite remission.
  • RCT showed less radiological progression in remission when treated with combination therapy compared to monotherapies.
  • CONCLUSION: Remission is a realistic treatment goal in early RA.
  • Radiological progression occurred in remission but is reduced by combination therapies.
  • ACR and DAS remission criteria are not directly comparable and standardization is needed.
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Databases, Factual. Humans. Meta-Analysis as Topic. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome. Tumor Necrosis Factor-alpha / antagonists & inhibitors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Rheumatol. 2010 Jul;37(7):1371-3 [20595289.001]
  • (PMID = 20516031.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents; 0 / Tumor Necrosis Factor-alpha
  •  go-up   go-down


43. Ranganath VK, Khanna D, Paulus HE: ACR remission criteria and response criteria. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-14-21
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ACR remission criteria and response criteria.
  • Many clinical studies now are geared toward evaluating the concept of eradicating inflammation as a method to seek the elusive goal of sustained remission in RA.
  • One of the first descriptions of remission in 'RA' was by Short et al in 1948, when he documented the natural progression of the disease.
  • Since that time, various criteria have been developed to define RA remission utilizing clinical, radiographic, and laboratory measures.
  • The most stringent of criteria is the American College of Rheumatology Remission Criteria, developed in 1980, which consists of clinical symptoms and signs of inflammation including fatigue, joint pain, morning stiffness, joint tenderness, joint swelling, and erythrocyte sedimentation rate (ESR).
  • Several reports have compared ACR remission criteria to Disease Activity Score (DAS) values to identify equivalent DAS remission values, and these have been extrapolated to modified versions of the DAS, the Simple Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI).
  • The ACR remission criteria and the response measures were not designed for use as the target or goal for the clinical management of individual RA patients in routine clinical practice.
  • Nevertheless, rheumatologists yearn for the eradication of inflammation in all RA patients, and attaining remission may be achievable in the future.
  • [MeSH-minor] Clinical Trials as Topic. Female. Humans. Male. Practice Guidelines as Topic / standards. Remission Induction. Research Design. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083757.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 52
  •  go-up   go-down


44. Pincus T, Kavanaugh A, Aletaha D, Smolen J: Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-1-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complexities in defining remission in rheumatic diseases.
  • The rheumatology community has devoted increasing attention to the subject of remission over the past 2 decades, on the basis of greater appreciation of the long-term severity of inflammatory rheumatic diseases and availability of new therapies and approaches to improve outcomes.
  • Nonetheless, description of remission in rheumatic diseases is complex, compared to many nonrheumatic diseases.
  • Recognition of remission requires a set of measures or an index rather than a single "gold standard."
  • Spontaneous remission is not infrequent in people with early inflammatory arthritis, including some who may meet criteria for rheumatoid arthritis (RA) over less than a few months, and may be confused with a drug-induced remission.
  • Remission may be transient in many patients over short periods, and the length of time required to maintain remission status varies in different reports.
  • Maintenance of a state of remission in autoimmune diseases that result from dysregulatory processes, rather than invasion of foreign cells or toxins, generally requires ongoing therapy indefinitely.
  • Patients who have organ damage or functional disability may be described as "in remission," although they are free of disease activity only, but not necessarily free of disease consequences.
  • A status of "low disease activity" or "near remission" with 70% to 90% of the features of an ideal remission may be adequate for many people with rheumatic diseases to avoid risks that may be required to reach 100% remission status.
  • Thus, the subject of remission remains under active discussion in the rheumatology community.
  • [MeSH-minor] Humans. Remission Induction. Secondary Prevention

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083755.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 76
  •  go-up   go-down


45. Narasimhan M, Kannaday MH: Treating depression and achieving remission. Asian J Psychiatr; 2010 Dec;3(4):163-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating depression and achieving remission.
  • Despite all the advances in understanding the biological underpinnings of depression and the extensive armamentarium of antidepressants remission is a difficult goal to achieve.
  • There are several hurdles to achieving remission including accuracy of diagnosis, partial response, suboptimization of the medication, and failure to capture residual symptoms.
  • There is an urgent need to implement strategies to achieve remission including destigmatizing mental illness, educating patients, their families, optimizing treatments, exploring novel interventions and addressing residual symptoms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010. Published by Elsevier B.V.
  • (PMID = 23050881.001).
  • [ISSN] 1876-2026
  • [Journal-full-title] Asian journal of psychiatry
  • [ISO-abbreviation] Asian J Psychiatr
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Schimmele CM, Wu Z, Penning MJ: Gender and remission of mental illness. Can J Public Health; 2009 Sep-Oct;100(5):353-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender and remission of mental illness.
  • The objective of this study was to determine whether gender also influences the timing of remission from illness.
  • The regression analysis undertaken considered remission in terms of all ICD-9 mental disorders (codes 290-314).
  • This analysis compares males and females on average length of treatment for mental illness and examines whether any gender differences in remission are generalized or disorder specific.
  • The target population represented all individuals with an ICD-9 diagnosis of mental illness who were treated through the Medical Services Plan in British Columbia.
  • RESULTS: There was a non-significant bivariate relation between gender and the timing of remission from mental illness.
  • However, the multivariate findings demonstrated that a significant gender effect on remission emerges after controls were introduced for demographic and socio-economic characteristics.
  • In particular, the timing of remission was somewhat longer for females.
  • CONCLUSIONS: The emergence of a significant effect after considering demographic and socio-economic characteristics suggests that a social disadvantage within the male sample (more single males) was suppressing a small negative effect of female gender on the timing of remission.
  • In other words, a social disadvantage among males concealed an unexplained female disadvantage in remission.

  • Genetic Alliance. consumer health - Mental Illness.
  • MedlinePlus Health Information. consumer health - Mental Disorders.
  • MedlinePlus Health Information. consumer health - Mental Health.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19994736.001).
  • [ISSN] 0008-4263
  • [Journal-full-title] Canadian journal of public health = Revue canadienne de sante publique
  • [ISO-abbreviation] Can J Public Health
  • [Language] ENG
  • [Grant] United States / NICHD NIH HHS / HD / R24 HD042828; None / None / / R24 HD042828-10; United States / NICHD NIH HHS / HD / R24 HD042828-10; Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  •  go-up   go-down


47. Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F: Maintenance of remission in Crohn's disease. Digestion; 2005;71(1):41-8
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance of remission in Crohn's disease.
  • When remission of Crohn's disease is achieved, the next goal is to maintain long-term remission.
  • Aminosalicylates may be recommended for maintenance remission, even though the results are less consistent than those observed in ulcerative colitis.
  • Corticosteroids are not effective in maintaining remission and should not be used for this indication.
  • Azathioprine and 6-mercaptopurine are effective in maintaining remission.
  • Methotrexate has also been found to be effective in maintaining remission in Crohn's disease in patients who have responded acutely to methotrexate.
  • Mycophenolate mofetil could be considered a therapy in patients who are either allergic to azathioprine or in whom azathioprine failed to induce remission.
  • In patients refractory to other therapies, infliximab may be effective in maintaining remission.
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Drug Therapy, Combination. Gastrointestinal Agents / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2005 S. Karger AG, Basel.
  • (PMID = 15711049.001).
  • [ISSN] 0012-2823
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Gastrointestinal Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 63
  •  go-up   go-down


48. Ravelli A, Martini A: Remission in juvenile idiopathic arthritis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S105-10
MedlinePlus Health Information. consumer health - Juvenile Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in juvenile idiopathic arthritis.
  • Until recently, no uniform and widely accepted criteria for defining remission in juvenile idiopathic arthritis (JIA) were available.
  • In recent years, a set of preliminary criteria for clinical remission in JIA was developed through an international collaborative effort.
  • These criteria enable the classification of patients in the states of inactive disease, clinical remission with medication, and clinical remission without medication.
  • A few studies have applied the new remission criteria in series of patients with JIA, with results that concur with those of previous surveys in showing that only a few patients with JIA have a chance of remaining in long-term remission status without medications.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Inflammation / drug therapy. Inflammation / physiopathology. Remission Induction. Survivors

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083772.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 31
  •  go-up   go-down


49. Leucht S, Lasser R: The concepts of remission and recovery in schizophrenia. Pharmacopsychiatry; 2006 Sep;39(5):161-70
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The concepts of remission and recovery in schizophrenia.
  • OBJECTIVE: To examine the past and current research into the concepts of remission and recovery in schizophrenia.
  • DATA SOURCES: An electronic literature search of studies published between January 1990-April 2005 examining the concepts of remission and recovery in schizophrenia and the treatment of schizophrenia with antipsychotic agents was performed using Medline and EMBASE.
  • Primary research parameters were 'schizophrenia', 'remission', 'recovery', 'meta-analysis', 'antipsychotics', 'atypicals', 'conventional', 'cognition', 'function' and 'quality of life'.
  • DATA SYNTHESIS: A number of different definitions of remission and recovery have been previously used, which has made comparison of study results problematic.
  • Recently, the first operational definition of remission, based on Diagnostic and Statistical Manual of Mental Disorders, fourth edition criteria (DSM-IV) for schizophrenia, was developed.
  • Recovery, which encompasses both symptom remission and more functional aspects of patient's well being, such as cognition, social functionality and quality of life, is still to be satisfactorily defined.
  • CONCLUSIONS: Until the definition for 'recovery' is further elucidated, factors such as symptom control and remission, and functional aspects of recovery such as improvements in cognition and social functioning, which are quantifiable, should be used as measures of treatment outcome and markers of recovery.

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944406.001).
  • [ISSN] 0176-3679
  • [Journal-full-title] Pharmacopsychiatry
  • [ISO-abbreviation] Pharmacopsychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Number-of-references] 77
  •  go-up   go-down


50. Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F: Maintenance of medically induced remission of Crohn's disease. Digestion; 2007;76(2):116-29
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maintenance of medically induced remission of Crohn's disease.
  • The natural history of Crohn's disease is characterized by recurring flares alternating with periods of inactive disease and remission.
  • This implies that most patients need to take medication for a large period of their life, mostly for maintenance of remission and, intermittently, additional therapy during a flare.
  • Low-dose systemic corticosteroids are not effective in maintaining remission and should not be used for this indication.
  • There is a trend towards a prolonged time to relapse in patients in remission who are treated with budenoside, a corticosteroid with high topical anti-inflammatory activity and low systemic activity.
  • Azathioprine and 6-mercaptopurine are effective in maintaining remission.
  • Methotrexate has also been found to be effective in maintaining remission in Crohn's disease in patients who have responded acutely to methotrexate.
  • In patients refractory to other therapies, infliximab may be effective in maintaining remission.
  • [MeSH-minor] Anti-Inflammatory Agents, Non-Steroidal / therapeutic use. Antibodies, Monoclonal / therapeutic use. Drug Therapy, Combination. Gastrointestinal Agents / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18239403.001).
  • [ISSN] 1421-9867
  • [Journal-full-title] Digestion
  • [ISO-abbreviation] Digestion
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antibodies, Monoclonal; 0 / Gastrointestinal Agents; 0 / Immunosuppressive Agents
  • [Number-of-references] 103
  •  go-up   go-down


51. Voskuyl AE, Dijkmans BA: Remission and radiographic progression in rheumatoid arthritis. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-37-40
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission and radiographic progression in rheumatoid arthritis.
  • Complete remission, defined as the presence of clinical as well as radiographic remission, is the ultimate goal of treatment of rheumatoid arthritis (RA).
  • Whether radiographic progression is entirely dependent on the presence of joint inflammation is a matter of debate; some evidence suggests that radiologic progression may continue in patients who appear clinically to be in remission.
  • Better diagnosis of joint damage will assist in our quest to attain and document full remission in RA.
  • Until these techniques are validated and assessed for predictive value, we would advocate that radiographic progression be added to existing criteria for clinical remission, in order to define remission in RA more comprehensively.
  • [MeSH-minor] Disease Progression. Humans. Predictive Value of Tests. Remission Induction. Severity of Illness Index

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083761.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 28
  •  go-up   go-down


52. Kotov AS, Rudakova IG, Kotov SV: [Non-terminal remission in epileptic patients]. Zh Nevrol Psikhiatr Im S S Korsakova; 2008;108(11):16-20
MedlinePlus Health Information. consumer health - Epilepsy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-terminal remission in epileptic patients].
  • Non-terminal remission (temporal stop of seizures with the following relapse) has been diagnosed in 18,3% of cases.
  • An aim of the study was to investigate clinical characteristics and prognosis in patients with such type of remission.
  • As a result, patients were diagnosed with idiopathic generalized epilepsy (18 cases), epilepsy with rare, usually secondary generalized, seizures (37 cases), drug-induced remission (46 cases) and long-term spontaneous remission usually associated with late childhood and adolescence (18 cases).
  • In conclusion, patients with non-terminal remission represent a heterogeneous group with different character of epileptic syndromes, forms of disease and prognosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008795.001).
  • [ISSN] 1997-7298
  • [Journal-full-title] Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • [ISO-abbreviation] Zh Nevrol Psikhiatr Im S S Korsakova
  • [Language] RUS
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


53. Olmsted MP, Kaplan AS, Rockert W: Defining remission and relapse in bulimia nervosa. Int J Eat Disord; 2005 Jul;38(1):1-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining remission and relapse in bulimia nervosa.
  • OBJECTIVE: The goals of the current study were to compare the relapse rates obtained when definitions of both remission and relapse were systematically varied and to propose some consensus definitions related to relapse in bulimia nervosa (BN).
  • RESULTS: Relapse rates at 19 months ranged from 21% to 55% depending on the definitions of remission and relapse applied.
  • DISCUSSION: Relapse rates are strongly influenced by definitions of remission and relapse.
  • We propose that partial remission, defined as a maximum of two symptom episodes per month for 2 months, should constitute eligibility for relapse and relapse should be defined as meeting full diagnostic criteria for 3 months.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 by Wiley Periodicals, Inc
  • [CommentIn] Int J Eat Disord. 2005 Jul;38(1):7-8 [15971234.001]
  • (PMID = 15971233.001).
  • [ISSN] 0276-3478
  • [Journal-full-title] The International journal of eating disorders
  • [ISO-abbreviation] Int J Eat Disord
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Degmecić D, Pozgain I, Filaković P, Dodig-Curković K, Mihanović M: Psychopharmacotherapy and remission of patients with schizophrenia. Coll Antropol; 2009 Jun;33(2):547-51
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Psychopharmacotherapy and remission of patients with schizophrenia.
  • Schizophrenia is a clinical syndrome of variable, but profoundly disruptive, psychopathology that involves cognition, emotion, perception and other aspects of behavior The Remission in Schizophrenia Working Group (RSWG) has defined criteria for symptomatic remission based on achieving and maintaining a consistently low symptom threshold for at least six consecutive months.
  • Aim of our study was to determine which antipsychotic are used in the treatment of patients with schizophrenia, as well as to assess are there differences between patients treated with typical and atypical antipsychotics and how many of them are in remission according to the defined remission criteria.
  • All of them were assessed with specially designed questionnaire about sociodemographic data, than with 8 item of PANSS (remission criteria), and with Clinical Global Impression scale.
  • Authors did not found statistically significant differences in two groups of patients regarding the scores on PANSS, CGI and number of patients in remission.
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Psychopharmacology. Remission Induction. Surveys and Questionnaires

  • Genetic Alliance. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19662777.001).
  • [ISSN] 0350-6134
  • [Journal-full-title] Collegium antropologicum
  • [ISO-abbreviation] Coll Antropol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


55. Patel V, Macdonald JK, McDonald JW, Chande N: Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2009;(4):CD006884
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methotrexate for maintenance of remission in Crohn's disease.
  • Although purine antimetabolites are moderately effective for maintenance of remission patients often relapse despite treatment with these agents.
  • OBJECTIVES: To conduct a systematic review of randomized trials examining the efficacy and safety of methotrexate for maintenance of remission in Crohn's disease.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) that compared methotrexate to placebo or any other active intervention for maintenance of remission in Crohn's disease were eligible for inclusion.
  • The main outcome measure was the proportion of patients maintaining clinical remission as defined by the studies and expressed as a percentage of the total number of patients randomized (intention to treat analysis).
  • A pooled analysis (n = 98) including one high quality trail (n = 76) showed that intramuscular methotrexate (15 mg/week) was significantly more effective than placebo for maintenance of remission in Crohn's disease (OR 3.11; 95% CI 1.31 to 7.41; P = 0.01).
  • A pooled analysis of two small studies (n = 50) showed no difference between methotrexate and 6-MP for maintenance of remission (OR 2.63; 95% CI 0.74 to 9.37; P = 0.14).
  • AUTHORS' CONCLUSIONS: Intramuscular methotrexate at a dose of 15 mg/week is safe and effective for maintenance of remission in Crohn's disease.
  • Oral methotrexate (12.5 to 15 mg/week) does not appear to be effective for maintenance of remission in Crohn's disease.
  • [MeSH-minor] Administration, Oral. Drug Administration Schedule. Humans. Injections, Intramuscular. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;8:CD006884 [25157445.001]
  • (PMID = 19821390.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; YL5FZ2Y5U1 / Methotrexate
  • [Number-of-references] 21
  •  go-up   go-down


56. Benchimol EI, Seow CH, Otley AR, Steinhart AH: Budesonide for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2009;(1):CD002913
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Budesonide for maintenance of remission in Crohn's disease.
  • BACKGROUND: Corticosteroids have been shown to be effective for induction, but not maintenance of remission in Crohn's disease.
  • Budesonide has been shown to be effective for induction of remission in Crohn's disease.
  • OBJECTIVES: To evaluate the efficacy and safety of oral budesonide for maintenance of remission in Crohn's disease.
  • The study population included patients of any age with Crohn's disease in remission.
  • The primary outcome was maintenance of remission at various reported follow-up times during the study, up to 12 months following enrollment.
  • Budesonide 6 mg daily was no more effective than placebo for maintenance of remission at 3 months (RR 1.25; 95% CI 1.00 to 1.58; P = 0.05), 6 months (RR 1.15; 95% CI 0.95 to 1.39; P = 0.14), or 12 months (RR 1.13; 95% CI 0.94 to 1.35; P = 0.19).
  • Budesonide was not more effective than weaning doses of prednisolone for maintenance of remission at 12 months (RR 0.79; 95% CI 0.55 to 1.13; P = 0.20), but was better than mesalamine 3 grams per day (RR of remission 2.51; 95% CI 1.03 to 6.12; P = 0.04).
  • No differences in efficacy were detected based on the different formulations of budesonide, methods used to induce remission, or budesonide dose.
  • AUTHORS' CONCLUSIONS: Budesonide is not more effective than placebo or weaning prednisolone for maintenance of remission in Crohn's disease.
  • Therefore, budesonide is not recommended for maintenance of remission in Crohn's disease.
  • [MeSH-minor] Administration, Oral. Humans. Randomized Controlled Trials as Topic. Recurrence. Remission Induction. Risk

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2014;8:CD002913 [25141071.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2001;(1):CD002913 [11279777.001]
  • (PMID = 19160212.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 51333-22-3 / Budesonide
  • [Number-of-references] 40
  •  go-up   go-down


57. Mahadevan U: TNF-alpha antagonists: benefits beyond remission. Rev Gastroenterol Disord; 2007;7 Suppl 1:S13-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TNF-alpha antagonists: benefits beyond remission.
  • The anti-tumor necrosis factor-a (TNF-a) agents infliximab, adalimumab, and certolizumab pegol have proven efficacy for induction and maintenance of remission among patients with moderate to severe Crohn's disease.
  • [MeSH-minor] Antibodies, Monoclonal. Humans. Remission Induction. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17392633.001).
  • [ISSN] 1533-001X
  • [Journal-full-title] Reviews in gastroenterological disorders
  • [ISO-abbreviation] Rev Gastroenterol Disord
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Tumor Necrosis Factors
  • [Number-of-references] 22
  •  go-up   go-down


58. Oakley A, Ng S: Grzybowski's generalized eruptive keratoacanthoma: remission with cyclophosphamide. Australas J Dermatol; 2005 May;46(2):118-23
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Grzybowski's generalized eruptive keratoacanthoma: remission with cyclophosphamide.
  • However, cyclophosphamide 100 mg daily for 1 month followed by 3 months at 200 mg daily resulted in remarkable improvement and eventual remission without further treatment.
  • [MeSH-major] Keratoacanthoma / diagnosis. Mouth Diseases / diagnosis
  • [MeSH-minor] Antineoplastic Agents, Alkylating / administration & dosage. Cyclophosphamide / administration & dosage. Diagnosis, Differential. Female. Humans. Lip / pathology. Middle Aged. Mouth Mucosa / pathology. Remission Induction

  • Genetic Alliance. consumer health - Keratoacanthoma.
  • MedlinePlus Health Information. consumer health - Mouth Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15842409.001).
  • [ISSN] 0004-8380
  • [Journal-full-title] The Australasian journal of dermatology
  • [ISO-abbreviation] Australas. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


59. Schinner S, Fritzen R, Schott M, Willenberg HS, Scherbaum WA: Spontaneous remission of primary hyperparathyroidism. Exp Clin Endocrinol Diabetes; 2007 Oct;115(9):619-21
Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of primary hyperparathyroidism.
  • The diagnosis of primary hyperparathyroidism (pHPT) is characterized by the constellation of elevated plasma serum calcium levels and low serum anorganic phosphate associated with inadequately high blood concentrations of parathyroid hormone (PTH).
  • Parathyroid adenomas are the main reason for this disorder and can frequently be detected by ultrasound examination.
  • Here we present the case of a 68-year-old man with spontaneous remission of primary hyperparathyroidism two years after the diagnosis was established.
  • The remission was documented by laboratory findings (normalisation of serum calcium and PTH levels) and by ultrasound examination that showed the disappearance of a cervical mass suggesting a parathyroid adenoma.
  • [MeSH-minor] Adenoma / ultrasonography. Aged. Calcium / blood. Humans. Male. Parathyroid Hormone / blood. Parathyroid Neoplasms / blood. Parathyroid Neoplasms / ultrasonography. Remission, Spontaneous

  • Genetic Alliance. consumer health - Hyperparathyroidism, primary.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17943699.001).
  • [ISSN] 0947-7349
  • [Journal-full-title] Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
  • [ISO-abbreviation] Exp. Clin. Endocrinol. Diabetes
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Parathyroid Hormone; SY7Q814VUP / Calcium
  •  go-up   go-down


60. Barber CE, Geldenhuys L, Hanly JG: Sustained remission of lupus nephritis. Lupus; 2006;15(2):94-101
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission of lupus nephritis.
  • The aim of this study was to describe the clinical course of patients with lupus nephritis (LN) who attain a sustained remission (SR) and identify predictors of SR.
  • Data was collected at diagnosis of LN (T0), at onset of remission (T1), and at final follow-up (T2).
  • Remission of LN was achieved following 37.7 +/- 6.8 months of therapy.
  • At diagnosis (T0) the WHO classification of nephritis, activity and chronicity scores of renal biopsies were comparable in the two groups.
  • Cumulative damage (SDI scores) in the SR group did not increase after patients entered remission (P = 0.250), whereas the mean SDI score in the control group increased significantly (P = 0.014) even when renal variables were excluded (P = 0.016).
  • Multivariate analysis revealed that female gender (P = 0.023), older age (P = 0.034), higher nonrenal SLEDAI scores (P = 0.016) at the time of diagnosis of LN and absence of azathioprine (P = 0.010) were predictive of SR.
  • It was concluded that remission of LN occurs in a substantial proportion of systemic lupus erythematosus (SLE) patients and may be sustained without maintenance immunosuppressive therapy.
  • [MeSH-minor] Adult. Antirheumatic Agents / therapeutic use. Azathioprine / therapeutic use. Creatinine / metabolism. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease Progression. Female. Humans. Hydroxychloroquine / therapeutic use. Logistic Models. Male. Multivariate Analysis. Remission Induction. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lupus.
  • MedlinePlus Health Information. consumer health - Steroids.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16539280.001).
  • [ISSN] 0961-2033
  • [Journal-full-title] Lupus
  • [ISO-abbreviation] Lupus
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antirheumatic Agents; 0 / Immunosuppressive Agents; 4QWG6N8QKH / Hydroxychloroquine; 8N3DW7272P / Cyclophosphamide; AYI8EX34EU / Creatinine; MRK240IY2L / Azathioprine
  •  go-up   go-down


61. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F: Probiotics for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2006;(4):CD004826
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probiotics for maintenance of remission in Crohn's disease.
  • BACKGROUND: Crohn's disease (CD) is characterised by episodes of disease activity and symptom-free remission.
  • OBJECTIVES: To assess the effectiveness of probiotics for the maintenance of remission in CD.
  • There was no statistically significant benefit of E. coli Nissle for reducing the risk of relapse compared to placebo (RR 0.43, 95% CI 0.15 to 1.20), or Lactobacillus GG after surgically-induced remission (RR 1.58, 95% CI 0.30 to 8.40) or medically-induced remission (RR 0.83, 95% CI 0.25 to 2.80).
  • AUTHORS' CONCLUSIONS: There is no evidence to suggest that probiotics are beneficial for the maintenance of remission in CD.
  • [MeSH-minor] Adult. Child. Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17054217.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Number-of-references] 50
  •  go-up   go-down


62. Xue SL, Wu DP, Sun AN, Tang XW: CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases. Am J Hematol; 2008 Feb;83(2):167-70
Hazardous Substances Data Bank. CYTARABINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CAG regimen enables relapsed or refractory T-cell acute lymphocytic leukemia patients to achieve complete remission: a report of six cases.
  • Patients with either relapsed or refractory T-cell acute lymphocytic leukemia (T-ALL) are candidates for allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • Achieving complete remission (CR) in these patients is difficult but crucial for the success of allo-HSCT.
  • After initial remission-induction therapy, two patients achieved CR, one showed a partial remission, and all relapsed soon.
  • The CAG regimen (cytosine arabinoside 10 mg/m(2) subcutaneously every 12 hr, day 1-14; aclarubicin 5-7 mg/m(2) intravenously daily, day 1-8; and concurrent use of G-CSF 200 microg/m(2)/day subcutaneously) was devised originally for the treatment of relapsed acute myelogenous leukemia.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Aclarubicin / administration & dosage. Adolescent. Adult. Antigens, CD / genetics. Cytarabine / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immunophenotyping. Karyotyping. Male. Middle Aged. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17874449.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 74KXF8I502 / Aclarubicin; CAG protocol
  •  go-up   go-down


63. Lasser RA, Nasrallah H, Helldin L, Peuskens J, Kane J, Docherty J, Tronco AT: Remission in schizophrenia: applying recent consensus criteria to refine the concept. Schizophr Res; 2007 Nov;96(1-3):223-31
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in schizophrenia: applying recent consensus criteria to refine the concept.
  • Although the concept of remission has been widely accepted and utilized in depression and anxiety disorders, there has been much less emphasis on defining remission in schizophrenia.
  • Recently, an expert consensus definition of remission in schizophrenia was proposed along specific operational criteria for the attainment of remission focusing on the three core dimensions of psychopathology identified within schizophrenia: psychoticism, disorganization and negative symptoms.
  • To date, the criteria have been applied retrospectively to several clinical studies, and these have demonstrated that the proposed definition of remission correlates significantly with established measures of symptom severity, functioning and quality of life, and appears achievable for a significant proportion of patients receiving at least 3 months of pharmacotherapy.
  • In this article we extend the notion of remission to include an examination of the possible association of several modifiable and unmodifiable factors and co-morbidities on remission status.
  • We also propose an investigation into the likelihood of different patient populations in achieving remission as well as assessing the impact of remission on health care costs and family burden.
  • Since cognitive dysfunction and negative symptoms may be strongly correlated with a lower likelihood of achieving remission, we recommend retrospective and/or prospective studies to determine the relationship between neurocognitive status and the predominance of negative symptoms at treatment start and the probability of achieving remission.
  • Taken together, these studies should help identify key predictors of remission, further define the remitted state, reduce therapeutic pessimism, raise treatment expectations and chart a strategy for further research in this important area.
  • [MeSH-major] Remission, Spontaneous. Schizophrenia / drug therapy. Schizophrenia / physiopathology

  • Genetic Alliance. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765480.001).
  • [ISSN] 0920-9964
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


64. Fransen J, van Riel PL: DAS remission cut points. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-29-32
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DAS remission cut points.
  • Values of DAS %lt;1.6 and DAS28 %lt; 2.6 correspond with an increased likelihood of being in remission.
  • This review presents development of the DAS and DAS28 remission cut points and their interpretation.
  • [MeSH-minor] Antirheumatic Agents / therapeutic use. Humans. Practice Guidelines as Topic. ROC Curve. Randomized Controlled Trials as Topic. Reference Values. Remission Induction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083759.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  • [Number-of-references] 20
  •  go-up   go-down


65. Shenoi S, Wallace CA: Remission in juvenile idiopathic arthritis: current facts. Curr Rheumatol Rep; 2010 Apr;12(2):80-6
MedlinePlus Health Information. consumer health - Juvenile Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in juvenile idiopathic arthritis: current facts.
  • Goals of treatment should include achievement of disease remission with optimal physical functioning that allows children to lead normal lives with no structural joint damage.
  • The term remission implies a complete lack of disease activity.
  • This article focuses on recently developed preliminary criteria for inactive disease and remission in JIA.
  • Recent studies using these new definitions demonstrate only modest rates of achievement of remission favoring children with persistent oligoarticular JIA.
  • Children with rheumatoid factor-positive polyarticular JIA are least likely to achieve remission.
  • Therapeutic strategies to achieve remission are also discussed.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Clinical Trials as Topic. Consensus. Delphi Technique. Disease Progression. Health Status. Humans. Recovery of Function. Remission Induction. Retrospective Studies. Rheumatoid Factor / blood. Severity of Illness Index

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Arthritis, Juvenile.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425015.001).
  • [ISSN] 1534-6307
  • [Journal-full-title] Current rheumatology reports
  • [ISO-abbreviation] Curr Rheumatol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 9009-79-4 / Rheumatoid Factor
  • [Number-of-references] 50
  •  go-up   go-down


66. Mäkinen H, Kautiainen H, Hannonen P, Sokka T: Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis; 2005 Oct;64(10):1410-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis?
  • OBJECTIVES: To study which cut off point of DAS28 corresponds to fulfilment of the American Rheumatism Association (ARA) preliminary remission criteria, and clinical remission criteria in patients with rheumatoid arthritis (RA).
  • METHODS: All adult patients diagnosed with RA at Jyväskylä Central Hospital 1997-98 were assessed for remission at 5 years.
  • Remission was defined as (a) ARA remission;.
  • (b) clinical remission (defined as no tender or swollen joints and normal erythrocyte sedimentation rate).
  • A receiver operating characteristics curve analysis was performed to calculate a cut off point of DAS28 that best corresponds to the ARA remission criteria and the clinical remission criteria.
  • At 5 years, 19 (12%) patients met the ARA remission criteria, and 55 (34%) met the clinical remission criteria.
  • The cut off value of DAS28 was 2.32 for the ARA remission criteria, and 2.68 for the clinical remission criteria.
  • CONCLUSION: In this study the DAS28 cut off point for the ARA remission was lower than in previous studies.
  • The cut off point for DAS28 remission remains controversial.
  • A substantial proportion of patients below the DAS28 cut off point for remission have tender or swollen joints, or both.
  • DAS28 may not be an appropriate tool for assessment of remission in RA.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Blood Sedimentation. Female. Humans. Male. Middle Aged. Predictive Value of Tests. ROC Curve. Remission Induction. Treatment Outcome


67. Iwata Y, Wada T, Uchiyama A, Miwa A, Nakaya I, Tohyama T, Yamada Y, Kurokawa T, Yoshida T, Ohta S, Yokoyama H, Iida H: Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia. Intern Med; 2006;45(22):1291-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of IgA nephropathy after allogeneic peripheral blood stem cell transplantation followed by immunosuppression for acute lymphocytic leukemia.
  • We report a case with immunoglobulin A (IgA) nephropathy, showing IgA deposition which disappeared after peripheral blood stem cell transplantation (PBSCT) for acute lymphocytic leukemia (ALL).
  • After complete remission, urinary protein and hematuria remained at between (-) and (+/-).
  • [MeSH-major] Glomerulonephritis, IGA / complications. Glomerulonephritis, IGA / pathology. Immunosuppression. Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adult. Humans. Kidney / pathology. Male. Remission Induction

  • Genetic Alliance. consumer health - Transplantation.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17170503.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


68. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Boerescu D, Attiullah N: Remission in depressed outpatients: more than just symptom resolution? J Psychiatr Res; 2008 Aug;42(10):797-801
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in depressed outpatients: more than just symptom resolution?
  • OBJECTIVE: In treatment studies of depression remission is defined according to scores on symptom severity scales.
  • Normalization of functioning has often been mentioned as an important component of the definition of remission, though it is not used to identify remitted patients in studies of treatment efficacy.
  • Conceptually, the return of normal functioning should be as fundamental to the concept of remission as is symptom resolution because the presence of both symptoms and impaired functioning are core constructs in the diagnosis of mental disorders.
  • In the present report from the Rhode Island Methods to Improve Diagnostic Assessment and Services (MIDAS) project we examined the independent and additive association between level of severity of depressive symptoms and functional impairment in predicting depressed patients' subjective evaluation of their remission status.
  • RESULTS: Symptom severity, functional impairment from depression, and quality of life were significantly and highly intercorrelated, and each was significantly associated with remission status.
  • The results of a logistic regression analysis indicated that each of the three variables was a significant, independent, predictor of remission status.
  • DISCUSSION: In treatment studies of depression remission is narrowly defined in terms of symptom resolution.
  • Our results support broadening the concept of remission beyond symptom levels to include assessments of functioning and quality of life.
  • [MeSH-major] Activities of Daily Living / psychology. Depressive Disorder, Major / therapy. Outcome Assessment (Health Care) / methods. Quality of Life / psychology. Social Adjustment

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17986389.001).
  • [ISSN] 0022-3956
  • [Journal-full-title] Journal of psychiatric research
  • [ISO-abbreviation] J Psychiatr Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


69. Nasrallah HA, Lasser R: Improving patient outcomes in schizophrenia: achieving remission. J Psychopharmacol; 2006 Nov;20(6 Suppl):57-61
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Improving patient outcomes in schizophrenia: achieving remission.
  • The Remission in Schizophrenia Working Group has recently proposed a consensus definition of remission in schizophrenia and, based on this definition, has developed specific operational criteria for the assessment of remission.
  • The aim of this article was to assess the application of these consensus criteria and to discuss the barriers for achieving remission.
  • An electronic literature search of studies published between January 1990 and December 2005 examining the concepts of remission, compliance and patient satisfaction in schizophrenia was performed using Medline and EMBASE.
  • The primary research parameters were 'schizophrenia', 'remission', 'antipsychotics', 'atypicals' and 'conventional'.
  • To date, the remission criteria have been applied retrospectively to a number of clinical studies, and these have demonstrated that the proposed definition of remission correlates significantly with established measures of symptom severity, functioning and quality of life, and appears achievable and sustainable for a significant proportion of patients receiving pharmacotherapy.
  • The atypical antipsychotic agents have been shown to impact favourably upon certain factors that play an integral part in the achievement of remission, such as negative symptoms, cognitive impairment, social functioning and quality of life.
  • The use of long-acting antipsychotic agents, with their assured medication delivery, may facilitate compliance and improve long-term treatment outcomes, possibly assisting patients in achieving remission.
  • Remission may, therefore, be considered as a current goal of treatment today, not a distant future aim.
  • [MeSH-minor] Attitude of Health Personnel. Delayed-Action Preparations. Humans. Patient Compliance. Remission, Spontaneous. Secondary Prevention. Social Adjustment. Treatment Outcome

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17046987.001).
  • [ISSN] 0269-8811
  • [Journal-full-title] Journal of psychopharmacology (Oxford, England)
  • [ISO-abbreviation] J. Psychopharmacol. (Oxford)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; 0 / Delayed-Action Preparations
  • [Number-of-references] 51
  •  go-up   go-down


70. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerescu D: How should remission from depression be defined? The depressed patient's perspective. Am J Psychiatry; 2006 Jan;163(1):148-50
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How should remission from depression be defined? The depressed patient's perspective.
  • OBJECTIVE: Although experts in the treatment of depression have suggested that achieving remission is the primary goal of treatment, questions remain about how remission should be defined.
  • In antidepressant efficacy trials, remission is defined according to scores on symptom severity scales.
  • Normalization of functioning is often mentioned as an important component of remission, although it is not used to identify patients with remission in treatment studies.
  • The authors' goal was to determine what depressed patients consider important in defining remission from depression.
  • They were asked to rate the importance of 16 statements in determining whether depression is in remission.
  • RESULTS: The three items most frequently judged to be very important in determining remission were the presence of features of positive mental health such as optimism and self-confidence; a return to one's usual, normal self; and a return to usual level of functioning.
  • [MeSH-major] Attitude to Health. Depressive Disorder, Major / psychology. Depressive Disorder, Major / therapy. Health Status

  • Genetic Alliance. consumer health - Depression.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16390903.001).
  • [ISSN] 0002-953X
  • [Journal-full-title] The American journal of psychiatry
  • [ISO-abbreviation] Am J Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Sesin CA, Bingham CO 3rd: Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum; 2005 Dec;35(3):185-96
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in rheumatoid arthritis: wishful thinking or clinical reality?
  • OBJECTIVES: To review the concept of remission in rheumatoid arthritis (RA), as defined by the Food and Drug Administration (FDA), the American College of Rheumatology (ACR), and the European League Against Rheumatism (EULAR).
  • To delineate differences between significant clinical improvements, very low disease activity, and the achievement of true remission.
  • METHODS: The MEDLINE database was searched for the key words "remission" and "rheumatoid arthritis."
  • We review 3 well-defined sets of criteria established by the ACR, EULAR, and the FDA for measuring remission.
  • RESULTS: Defining remissions in clinical trials and clinical practice requires appropriate standardized and objective outcome measures, such as the ACR and EULAR remission criteria.
  • Remission, as defined by the ACR criteria, has been observed in 7 to 22% of patients treated with traditional DMARD monotherapy (ie, gold, penicillamine, methotrexate [MTX], cyclosporine A, or sulfasalazine), but these remissions have often been short-lived.
  • Treatments with DMARD combinations, biologic monotherapy, and biologic combination therapy with MTX offer greater hope and may facilitate the higher rates of remission.
  • Clinical trial results have shown that newer DMARDs such as leflunomide or the combination of multiple DMARDs can generally elicit greater EULAR remission rates (ranging from 13 to 42%) than monotherapies.
  • Biologic combinations with MTX have also been shown to induce significant remission (as defined by the EULAR criteria) in RA patients, with a 31% rate observed with infliximab plus MTX at 54 weeks, a 50% rate observed for adalimumab plus MTX after 2 years of therapy, and a 41% rate observed for etanercept plus MTX after 2 years of therapy.
  • CONCLUSIONS: In the era of biologics and combination therapy, identifying remission or at least very low disease activity as the ultimate goal in RA therapy should become the new standard for the outcome of all RA trials.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Practice Guidelines as Topic. Remission Induction. Retrospective Studies. Severity of Illness Index. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16325659.001).
  • [ISSN] 0049-0172
  • [Journal-full-title] Seminars in arthritis and rheumatism
  • [ISO-abbreviation] Semin. Arthritis Rheum.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antirheumatic Agents
  •  go-up   go-down


72. Sieber-Ruckstuhl NS, Kley S, Tschuor F, Zini E, Ohlerth S, Boretti FS, Reusch CE: Remission of diabetes mellitus in cats with diabetic ketoacidosis. J Vet Intern Med; 2008 Nov-Dec;22(6):1326-32
Zurich Open Access Repository and Archive. Full text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of diabetes mellitus in cats with diabetic ketoacidosis.
  • HYPOTHESIS/OBJECTIVES: Cats initially diagnosed with DKA can achieve remission from diabetes.
  • Cats with DKA and diabetic remission are more likely to have been administered glucocorticoids before diagnosis.
  • Diabetic remission was defined as being clinically unremarkable for at least 1 month after insulin withdrawal.
  • (1) cats with DKA and diabetic remission;.
  • (2) cats with DKA without diabetic remission; and (3) cats with DM and diabetic remission.
  • RESULTS: Seven cats with DKA had remission from diabetes.
  • These cats had significantly higher concentrations of leukocytes and segmented neutrophils, and significantly lower concentrations of eosinophils in blood and had pancreatic disease more often than did cats with uncomplicated DM and diabetic remission.
  • CONCLUSIONS AND CLINICAL IMPORTANCE: Remission of DM in cats presenting with DKA is possible.
  • Cats with DKA and remission have more components of a stress leucogram, pancreatic disease, and seemed to be treated more often with glucocorticoids than cats with uncomplicated DM and diabetic remission.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19000245.001).
  • [ISSN] 0891-6640
  • [Journal-full-title] Journal of veterinary internal medicine
  • [ISO-abbreviation] J. Vet. Intern. Med.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids
  •  go-up   go-down


73. Polanco N, Gutiérrez E, Covarsí A, Ariza F, Carreño A, Vigil A, Baltar J, Fernández-Fresnedo G, Martín C, Pons S, Lorenzo D, Bernis C, Arrizabalaga P, Fernández-Juárez G, Barrio V, Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A, Fernández-Vega F, Praga M, Grupo de Estudio de las Enfermedades Glomerulares de la Sociedad Española de Nefrología: Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol; 2010 Apr;21(4):697-704
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy.
  • Spontaneous remission is a well known characteristic of idiopathic membranous nephropathy, but contemporary studies describing predictors of remission and long-term outcomes are lacking.
  • Spontaneous remission occurred in 104 (32%) patients: proteinuria progressively declined after diagnosis until remission of disease at 14.7 +/- 11.4 months.
  • Although spontaneous remission was more frequent with lower levels of baseline proteinuria, it also frequently occurred in patients with massive proteinuria: 26% among those with baseline proteinuria 8 to 12 g/24 h and 22% among those with proteinuria >12 g/24 h.
  • Baseline serum creatinine and proteinuria, treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor antagonists, and a >50% decline of proteinuria from baseline during the first year of follow-up were significant independent predictors for spontaneous remission.
  • The incidence of death and ESRD were significantly lower among patients with spontaneous remission.
  • In conclusion, spontaneous remission is common among patients with nephrotic syndrome resulting from membranous nephropathy and carries a favorable long-term outcome with a low incidence of relapse.
  • A decrease in proteinuria >50% from baseline during the first year predicts spontaneous remission.
  • [MeSH-minor] Cohort Studies. Female. Humans. Male. Middle Aged. Proteinuria / etiology. Remission, Spontaneous. Retrospective Studies

  • Genetic Alliance. consumer health - Membranous nephropathy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin J Am Soc Nephrol. 2009 Sep;4(9):1417-22 [19661220.001]
  • [Cites] Q J Med. 1986 Aug;60(232):793-802 [3774962.001]
  • [Cites] Kidney Int. 2001 Apr;59(4):1484-90 [11260412.001]
  • [Cites] Kidney Int. 2001 May;59(5):1983-94 [11318974.001]
  • [Cites] Ann Intern Med. 2001 Jul 17;135(2):73-87 [11453706.001]
  • [Cites] Kidney Int. 2002 Jan;61(1):219-27 [11786104.001]
  • [Cites] Lancet. 2002 Sep 21;360(9337):923-4 [12354476.001]
  • [Cites] Nephrol Dial Transplant. 2004 May;19(5):1142-8 [14993502.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):898-904 [15327378.001]
  • [Cites] Kidney Int. 2004 Sep;66(3):1199-205 [15327418.001]
  • [Cites] Am J Kidney Dis. 2004 Sep;44(3):385-401 [15332211.001]
  • [Cites] Am J Kidney Dis. 2004 Sep;44(3):562-6 [15332231.001]
  • [Cites] Am J Med. 1979 Jan;66(1):82-90 [420255.001]
  • [Cites] N Engl J Med. 1979 Dec 13;301(24):1301-6 [388220.001]
  • [Cites] Clin Nephrol. 1984 Aug;22(2):61-7 [6478673.001]
  • [Cites] Clin J Am Soc Nephrol. 2008 May;3(3):905-19 [18235148.001]
  • [Cites] Kidney Int. 1988 Mar;33(3):708-15 [3367560.001]
  • [Cites] N Engl J Med. 1989 Jan 5;320(1):8-13 [2642605.001]
  • [Cites] Am J Kidney Dis. 1992 Sep;20(3):240-8 [1519604.001]
  • [Cites] Nephrol Dial Transplant. 1992;7 Suppl 1:85-90 [1337188.001]
  • [Cites] N Engl J Med. 1993 Jul 8;329(2):85-9 [8510707.001]
  • [Cites] Nephrol Dial Transplant. 1995;10(1):25-9 [7724024.001]
  • [Cites] Kidney Int. 1997 Mar;51(3):901-7 [9067928.001]
  • [Cites] Nephrol Dial Transplant. 1998 Feb;13(2):443-8 [9509460.001]
  • [Cites] J Am Soc Nephrol. 2005 May;16(5):1188-94 [15800117.001]
  • [Cites] Am J Kidney Dis. 2005 Dec;46(6):1012-29 [16310567.001]
  • [Cites] Am J Kidney Dis. 2006 Feb;47(2):233-40 [16431252.001]
  • [Cites] Kidney Int. 2007 May;71(9):924-30 [17377504.001]
  • [Cites] Nephrol Dial Transplant. 2007 May;22(5):1351-60 [17311833.001]
  • [Cites] J Am Soc Nephrol. 2007 Jun;18(6):1899-904 [17494881.001]
  • [CommentIn] J Am Soc Nephrol. 2010 Apr;21(4):551-2 [20299357.001]
  • (PMID = 20110379.001).
  • [ISSN] 1533-3450
  • [Journal-full-title] Journal of the American Society of Nephrology : JASN
  • [ISO-abbreviation] J. Am. Soc. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2844306
  •  go-up   go-down


74. Nishiwaki S, Inamoto Y, Sakamaki H, Kurokawa M, Iida H, Ogawa H, Fukuda T, Ozawa Y, Kobayashi N, Kasai M, Mori T, Iwato K, Yoshida T, Onizuka M, Kawa K, Morishima Y, Suzuki R, Atsuta Y, Miyamura K: Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission. Blood; 2010 Nov 18;116(20):4368-75
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allogeneic stem cell transplantation for adult Philadelphia chromosome-negative acute lymphocytic leukemia: comparable survival rates but different risk factors between related and unrelated transplantation in first complete remission.
  • To identify factors to improve the outcomes of related and unrelated allogeneic stem cell transplantations (allo-SCT) for Philadelphia chromosome-negative acute lymphocytic leukemia (Ph(-) ALL) in the first complete remission (CR1), we retrospectively analyzed 1139 Ph(-) ALL patients using the registry data, particularly the details of 641 patients transplanted in CR1.
  • Among patients transplanted in CR1, relapse rates were significantly higher in related allo-SCT compared with unrelated allo-SCT, and multivariate analysis demonstrated that less than 6 months from diagnosis to allo-SCT alone was associated with relapse.
  • On the other hand, nonrelapse mortality (NRM) was significantly higher in unrelated allo-SCT compared with related allo-SCT, and multivariate analysis demonstrated that 10 months or longer from diagnosis to allo-SCT, human leukocyte antigen mismatch, and abnormal karyotype were associated with NRM.
  • [MeSH-major] Philadelphia Chromosome. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Cause of Death. Humans. Middle Aged. Multivariate Analysis. Recurrence. Remission Induction. Risk Factors. Survival Rate. Tissue Donors. Transplantation, Homologous. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20664060.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Bandelow B: Defining response and remission in anxiety disorders: toward an integrated approach. CNS Spectr; 2006 Oct;11(10 Suppl 12):21-8
MedlinePlus Health Information. consumer health - Anxiety.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Defining response and remission in anxiety disorders: toward an integrated approach.
  • Response and remission rates are commonly used to evaluate the efficacy of treatments for anxiety disorders and other psychiatric illnesses.
  • Response is generally regarded as a clinically meaningful improvement in symptoms, while remission, the goal of treatment, is generally thought of as the absence or near absence of symptoms following illness, accompanied by a return to premorbid levels of functioning.
  • Response and remission are often defined using psychiatric rating scales, based on score cutoffs or the magnitude of score changes from baseline.
  • While no universally accepted criteria exist, a commonly used threshold for response is a >50% improvement in the total score, while for remission, various cutoff points have been used.
  • Comparison of cutoffs or change scores for disease-specific scales with Clinical Global Impressions ratings is a useful way of evaluating response and remission criteria across disorders.
  • To illustrate the use of disease-specific and global measures, this article summarizes data from randomized, placebo-controlled studies of adult patients with generalized anxiety disorder, social anxiety disorder, or panic disorder treated with the serotonin norepinephrine reuptake inhibitor venlafaxine extended release, for which acute-phase data are available (a total of 13 trials).

  • Genetic Alliance. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008827.001).
  • [ISSN] 1092-8529
  • [Journal-full-title] CNS spectrums
  • [ISO-abbreviation] CNS Spectr
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Cyclohexanols; 0 / Delayed-Action Preparations; 7D7RX5A8MO / Venlafaxine Hydrochloride
  • [Number-of-references] 33
  •  go-up   go-down


76. Aletaha D, Smolen JS: Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-45-51
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission of rheumatoid arthritis: should we care about definitions?
  • A state of remission can be achieved in more and more rheumatoid arthritis (RA) patients.
  • Remission can be defined by two different approaches: one using a categorical model, requiring criteria for multiple variables to be fulfilled, each with its own threshold value (remission "criteria"); the other using a dimensional model, providing single measures of activity, which allow definition of remission by a single cut point (remission cut points for composite indices).
  • The face validity of remission as defined by composite indices surpasses the one for the "criteria".
  • Likewise, the ones that are not weighted seem to surpass the weighted ones, as can be seen by the significant proportion of patients that continues to have considerable swollen joint counts despite being in Disease Activity Score (DAS)-28 remission.
  • All composite indices seem to perform similarly well as tests for remission using expert judgments as the gold standard.
  • [MeSH-minor] Humans. Patient Satisfaction. Recovery of Function. Reference Values. Remission Induction

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083763.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 39
  •  go-up   go-down


77. Emsley R, Oosthuizen PP, Kidd M, Koen L, Niehaus DJ, Turner HJ: Remission in first-episode psychosis: predictor variables and symptom improvement patterns. J Clin Psychiatry; 2006 Nov;67(11):1707-12
Hazardous Substances Data Bank. HALOPERIDOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission in first-episode psychosis: predictor variables and symptom improvement patterns.
  • Recently proposed operationally defined criteria for remission provide an opportunity to readdress this topic.
  • METHOD: We applied the remission criteria to a sample of 57 subjects with first-episode psychosis (DSM-IV schizophrenia, schizoaffective disorder, or schizophreniform disorder), treated according to a fixed protocol in a prospective study.
  • Various demographic, baseline clinical, and early-response variables were subjected to discriminant analysis for their ability to predict remission or nonremission.
  • Symptom reduction at 6 weeks, including core psychotic symptoms, was significant in both groups (remitters, p < .0001; nonremitters, p < .0001), although reduction was substantially greater in the remission group (p = .004).
  • Thereafter, the remission group continued to improve (p < .01), while the nonremitting group failed to do so (p = .55).
  • CONCLUSION: A combination of demographic, baseline clinical, and acute treatment response variables may accurately predict treatment outcome.
  • Persistent noncore psychotic symptoms in subjects meeting proposed remission criteria require further investigation.
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Male. Predictive Value of Tests. Prospective Studies. Remission Induction

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17196049.001).
  • [ISSN] 1555-2101
  • [Journal-full-title] The Journal of clinical psychiatry
  • [ISO-abbreviation] J Clin Psychiatry
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; J6292F8L3D / Haloperidol
  •  go-up   go-down


78. Urowitz MB, Feletar M, Bruce IN, Ibañez D, Gladman DD: Prolonged remission in systemic lupus erythematosus. J Rheumatol; 2005 Aug;32(8):1467-72
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prolonged remission in systemic lupus erythematosus.
  • OBJECTIVE: To determine the frequency of prolonged remission in systemic lupus erythematosus (SLE) using strict criteria for remission and to define disease characteristics and prognosis of patients achieving this state.
  • To also determine the frequency of remission utilizing less restrictive definitions, such as allowing shorter period of disease quiescence, persistence of serological activity, or treatment in the absence of clinical disease.
  • Prolonged remission was defined as a 5-year consecutive period of no disease activity (SLE disease activity index, SLEDAI = 0) and without treatment (corticosteroids, antimalarials, or immunosuppressants).
  • Of the 703 patients 46 (6.5%) achieved complete remission for at least 1 year, whereas only 12 patients (1.7%) had prolonged complete remission of at least 5 years on no treatment.
  • Although the frequency of disease manifestations was similar to the patients not in remission, the 5-year remission group was distinguished by lower overall disease activity as measured by adjusted mean SLEDAI, lower prevalence of anti-DNA antibodies, and lower use of steroids and antimalarials.
  • CONCLUSION: Prolonged complete remission in lupus is rare.
  • [MeSH-minor] Adult. Antibodies, Antinuclear / blood. Antimalarials / therapeutic use. Databases, Factual. Female. Humans. Male. Middle Aged. Prognosis. Remission Induction. Seroepidemiologic Studies. Steroids / therapeutic use. Time Factors

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16078321.001).
  • [ISSN] 0315-162X
  • [Journal-full-title] The Journal of rheumatology
  • [ISO-abbreviation] J. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antimalarials; 0 / Immunosuppressive Agents; 0 / Steroids
  •  go-up   go-down


79. Valesini G, Di Franco M, Spinelli FR, Scrivo R: Induction of remission in rheumatoid arthritis: criteria and opportunities. Rheumatol Int; 2008 Dec;29(2):131-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of remission in rheumatoid arthritis: criteria and opportunities.
  • The concept of remission in rheumatology is complicated by the lack of a single gold standard measurement, spontaneous remissions and the usage of several sets of remission criteria.
  • Feasibility is reduced by traditional clinical practice, which does not include remission criteria monitoring.
  • Remission is important to prevent joint destruction, preserve adequate quality of life and prevent disability.
  • [MeSH-minor] Disability Evaluation. Drug Therapy, Combination. Humans. Quality of Life. Randomized Controlled Trials as Topic. Remission Induction. Treatment Outcome

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18807254.001).
  • [ISSN] 0172-8172
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antirheumatic Agents
  • [Number-of-references] 46
  •  go-up   go-down


80. Cohen G, Gossec L, Dougados M, Cantagrel A, Goupille P, Daures JP, Rincheval N, Combe B: Radiological damage in patients with rheumatoid arthritis on sustained remission. Ann Rheum Dis; 2007 Mar;66(3):358-63
MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological damage in patients with rheumatoid arthritis on sustained remission.
  • OBJECTIVE: To assess the radiological damage progression in patients with recent rheumatoid arthritis in sustained remission.
  • Patients in remission (DAS<1.6) at the 3-year and 5-year time points were compared with patients with a persistently active rheumatoid arthritis by Wilcoxon's signed rank test.
  • RESULTS: 57 patients died, were lost to follow-up or had incomplete data; 30 (15.7% of those who completed) patients were in remission at 3 and 5 years.
  • The SHS in these two groups was not significantly different at baseline (p = 0.15), but was lower in the remission group at 5 years (p = 0.0047).
  • The median (IQR) radiographic score increased from 0.5 (0-7) at baseline to 2.5 (0-14) after 5 years for the remission group (p = 0.18) and from 2 (0-7) to 13 (3-29) in the group with active rheumatoid arthritis (p<0.001).
  • 5 (16.7%) patients in remission had relevant progression of radiographic damage (ie, progression >4.1 points) and 6 (20%) presented new erosions in a previously unaffected joint between the third and the fifth years.
  • CONCLUSION: Patients with early rheumatoid arthritis in sustained remission did not present statistically significant radiographic degradation at the group level; nevertheless, 16.7% of these patients did present degradation.
  • Absence of progression should be part of the remission definition in rheumatoid arthritis.
  • [MeSH-minor] Adult. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Prospective Studies. Remission Induction. Severity of Illness Index

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rheumatology (Oxford). 2001 Mar;40(3):297-301 [11285377.001]
  • [Cites] Rheumatology (Oxford). 2000 Sep;39(9):1031-6 [10986311.001]
  • [Cites] Arthritis Rheum. 2001 Aug;44(8):1736-43 [11508423.001]
  • [Cites] Clin Exp Rheumatol. 2001 Sep-Oct;19(5):573-6 [11579719.001]
  • [Cites] Arthritis Rheum. 2001 Sep;44(9):2009-17 [11592361.001]
  • [Cites] J Rheumatol. 2002 Feb;29(2):267-70 [11842821.001]
  • [Cites] Arthritis Rheum. 2002 Feb;46(2):357-65 [11840437.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):894-8 [11953964.001]
  • [Cites] Arthritis Rheum. 2002 Apr;46(4):913-20 [11953967.001]
  • [Cites] J Rheumatol. 2002 Nov;29(11):2278-87 [12415582.001]
  • [Cites] Arthritis Rheum. 2002 Nov;46(11):2847-56 [12428224.001]
  • [Cites] Ann Rheum Dis. 2002 Dec;61(12):1055-9 [12429534.001]
  • [Cites] Ann Rheum Dis. 2003 Feb;62(2):120-6 [12525380.001]
  • [Cites] Arthritis Rheum. 2003 Jan;48(1):64-71 [12528105.001]
  • [Cites] Ann Rheum Dis. 2003 Aug;62(8):764-6 [12860733.001]
  • [Cites] J Rheumatol. 2003 Nov;30(11):2344-9 [14677175.001]
  • [Cites] J Rheumatol. 2003 Dec;30(12):2580-4 [14719197.001]
  • [Cites] Arthritis Rheum. 2004 Jan;50(1):1-4 [14730593.001]
  • [Cites] Arthritis Rheum. 2004 Jan;50(1):36-42 [14730597.001]
  • [Cites] J Rheumatol. 2004 Feb;31(2):214-22 [14760787.001]
  • [Cites] Semin Arthritis Rheum. 2004 Feb;33(4):264-72 [14978664.001]
  • [Cites] Ann Rheum Dis. 2004 Jun;63(6):675-80 [15140774.001]
  • [Cites] Arthritis Rheum. 1980 Feb;23(2):137-45 [7362664.001]
  • [Cites] Arthritis Rheum. 1981 Oct;24(10):1308-15 [7306232.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Arthritis Rheum. 1988 Mar;31(3):315-24 [3358796.001]
  • [Cites] Lancet. 1989 May 13;1(8646):1036-8 [2565997.001]
  • [Cites] Ann Rheum Dis. 1990 Nov;49(11):916-20 [2256738.001]
  • [Cites] J Rheumatol. 1993 Mar;20(3):579-81 [8478878.001]
  • [Cites] Arthritis Rheum. 1995 Jun;38(6):727-35 [7779114.001]
  • [Cites] Br J Rheumatol. 1995 Jun;34(6):529-34 [7633794.001]
  • [Cites] Br J Rheumatol. 1995 Nov;34 Suppl 2:74-8 [8535653.001]
  • [Cites] Arthritis Rheum. 1996 Jan;39(1):34-40 [8546736.001]
  • [Cites] Arthritis Rheum. 1996 Jan;39(1):115-24 [8546720.001]
  • [Cites] Arthritis Rheum. 1996 Jun;39(6):996-1005 [8651994.001]
  • [Cites] Br J Rheumatol. 1996 Nov;35(11):1101-5 [8948296.001]
  • [Cites] Br J Rheumatol. 1996 Nov;35(11):1106-15 [8948297.001]
  • [Cites] Br J Rheumatol. 1996 Dec;35(12):1263-8 [9010054.001]
  • [Cites] Br J Rheumatol. 1997 Feb;36(2):225-8 [9133935.001]
  • [Cites] Arthritis Rheum. 1998 Sep;41(9):1571-82 [9751089.001]
  • [Cites] Br J Rheumatol. 1998 Dec;37(12):1324-9 [9973158.001]
  • [Cites] J Rheumatol. 1999 Mar;26(3):705-11 [10090187.001]
  • [Cites] J Rheumatol. 1999 Mar;26(3):731-9 [10090192.001]
  • [Cites] Ann Rheum Dis. 1999 Apr;58(4):220-5 [10364900.001]
  • [Cites] Ann Rheum Dis. 1999 May;58(5):323 [10498581.001]
  • [Cites] Ann Rheum Dis. 1999 Oct;58(10):618-22 [10491360.001]
  • [Cites] Arthritis Rheum. 2004 Nov;50(11):3734-5 [15529382.001]
  • [Cites] Arthritis Rheum. 2005 Apr;52(4):1020-30 [15818697.001]
  • [Cites] J Rheumatol. 2005 May;32(5):796-800 [15868611.001]
  • [Cites] Arthritis Rheum. 2005 Nov;52(11):3360-70 [16255010.001]
  • [Cites] Semin Arthritis Rheum. 2005 Dec;35(3):185-96 [16325659.001]
  • [Cites] Arthritis Rheum. 2000 Oct;43(10):2143-51 [11037873.001]
  • [Cites] Arthritis Rheum. 2000 Feb;43(2):386-9 [10693879.001]
  • [Cites] Rheumatology (Oxford). 2000 Jun;39(6):603-11 [10888704.001]
  • [Cites] Rheumatology (Oxford). 2000 Sep;39(9):939-49 [10986297.001]
  • [Cites] Rheum Dis Clin North Am. 2001 May;27(2):389-403, ix-x [11396099.001]
  • (PMID = 16935911.001).
  • [ISSN] 0003-4967
  • [Journal-full-title] Annals of the rheumatic diseases
  • [ISO-abbreviation] Ann. Rheum. Dis.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1856000
  •  go-up   go-down


81. Werbrouck B, Meire V, De Bleecker JL: Multiple neurological syndromes during Hodgkin lymphoma remission. Acta Neurol Belg; 2005 Mar;105(1):48-50
MedlinePlus Health Information. consumer health - Hodgkin Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple neurological syndromes during Hodgkin lymphoma remission.
  • We report a young patient who developed a stiff man syndrome (SMS) long after remission of Hodgkin lymphoma.
  • This patient is remarkable because he has had several other potentially autoimmune or paraneoplastic neurological syndromes including limbic encephalitis and demyelinating polyneuropathy which also occurred years after remission from Hodgkin disease.
  • [MeSH-minor] Adult. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15861997.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


82. Wunderink L, Nienhuis FJ, Sytema S, Wiersma D: Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics. Schizophr Bull; 2007 May;33(3):792-6
MedlinePlus Health Information. consumer health - Schizophrenia.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.
  • The objective of this study was to examine the predictive validity of the remission criteria proposed by Andreasen et al in first-episode patients responding to antipsychotics.
  • Antipsychotic responsive patients with first-episode schizophrenia showing symptom remission (n = 60) were compared with patients who did not fulfill the proposed criteria (n = 65).
  • Patients in the remission group showed a significantly better outcome during follow-up on all Positive and Negative Syndrome Scale subscale scores (positive, negative, and general symptom subscales) and a significantly higher level of social functioning.
  • The proposed multidimensional criteria for symptomatic remission convey significant information when applied to first-episode patients who responded to antipsychotics, predicting outcome on the domains of both psychopathology and social functioning.
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Female. Humans. Longitudinal Studies. Male. Middle Aged. Netherlands. Prognosis. Psychiatric Status Rating Scales / statistics & numerical data. Psychometrics. Quality of Life. Social Adjustment. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Psychiatr Scand. 2006 Apr;113(4):332-9 [16638078.001]
  • [Cites] Acta Psychiatr Scand. 2006 Feb;113(2):91-5 [16423159.001]
  • [Cites] Qual Life Res. 2000 Feb;9(1):121-4 [10981212.001]
  • [Cites] Br J Psychiatry. 2001 Jun;178:506-17 [11388966.001]
  • [Cites] Schizophr Bull. 2002;28(2):203-22 [12693428.001]
  • [Cites] Am J Psychiatry. 2004 Mar;161(3):473-9 [14992973.001]
  • [Cites] Schizophr Bull. 1987;13(2):261-76 [3616518.001]
  • [Cites] Schizophr Bull. 1988;14(4):633-43 [3064287.001]
  • [Cites] Int J Rehabil Res. 1988;11(3):213-24 [2978514.001]
  • [Cites] Arch Gen Psychiatry. 1993 May;50(5):369-76 [8098203.001]
  • [Cites] Am J Psychiatry. 1994 Oct;151(10):1409-16 [8092334.001]
  • [Cites] Eur Child Adolesc Psychiatry. 1997 Dec;6(4):212-8 [9443000.001]
  • [Cites] J Nerv Ment Dis. 1998 Jun;186(6):357-63 [9653420.001]
  • [Cites] Am J Psychiatry. 2005 Mar;162(3):441-9 [15741458.001]
  • [Cites] Schizophr Bull. 2005 Jul;31(3):723-34 [16020553.001]
  • [Cites] Am J Psychiatry. 2000 May;157(5):808-15 [10784476.001]
  • (PMID = 16894026.001).
  • [ISSN] 0586-7614
  • [Journal-full-title] Schizophrenia bulletin
  • [ISO-abbreviation] Schizophr Bull
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Other-IDs] NLM/ PMC2526146
  •  go-up   go-down


83. Nihlén U, Greiff L, Montnémery P, Löfdahl CG, Johannisson A, Persson C, Andersson M: Incidence and remission of self-reported allergic rhinitis symptoms in adults. Allergy; 2006 Nov;61(11):1299-304
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Incidence and remission of self-reported allergic rhinitis symptoms in adults.
  • BACKGROUND: A few studies have examined the incidence and remission of allergic rhinitis (AR) in the same general population.
  • Multiple logistic regression adjusted for age and gender was used to analyze potential predictors, reported in 1992, for incidence and remission of AR.
  • The incidence of AR from 1992 to 2000 was 4.8%, while 23.1% of the cases with AR in 1992 stated no AR symptoms in 2000 indicating remission.
  • The highest incidence was seen in the youngest age group (20-29 years), whereas remission was highest in the oldest age group (50-59 years).
  • Asthma symptoms during the last year (as reported in 1992) predicted increased incidence of AR and less chance for remission, 1.89 (95%CI 1.08-3.31) and 0.52 (0.31-0.87), respectively.
  • Family histories of AR or asthma predicted increased incidence of AR 1.99 (1.42-2.80) and 1.62 (1.10-2.37), respectively, but were not associated with chance for remission, OR = 1.23 (0.81-1.87) and 0.94 (0.60-1.48).
  • CONCLUSION: This study showed that AR became more common between 1992 and 2000, but also indicated remission in about 20% of the cases within the 8-year period, particularly in older ages.
  • Asthma seems to be associated with higher risk for AR as well as less chance for remission, while heredity of asthma (or AR) may only be associated with the risk for the development and not remission of AR.
  • [MeSH-minor] Adult. Female. Humans. Incidence. Male. Middle Aged. Remission, Spontaneous. Surveys and Questionnaires. Sweden / epidemiology

  • Genetic Alliance. consumer health - Allergic rhinitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17002705.001).
  • [ISSN] 0105-4538
  • [Journal-full-title] Allergy
  • [ISO-abbreviation] Allergy
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  •  go-up   go-down


84. Trivedi MH: Treating depression to full remission. J Clin Psychiatry; 2009 Jan;70(1):e01
Genetic Alliance. consumer health - Depression.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating depression to full remission.
  • For more than a decade, the goal of major depressive disorder treatment has been achieving and sustaining remission, which involves complete resolution of depressive symptoms and a return to previous levels of mental and physical functioning.
  • Consulting clinical guidelines and findings of clinical trials that include remission as a primary outcome measure may also help clinicians to improve remission rates among their patients.
  • [MeSH-major] Depressive Disorder, Major / therapy. Evidence-Based Medicine

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 Physicians Postgraduate Press, Inc.
  • (PMID = 19222976.001).
  • [ISSN] 1555-2101
  • [Journal-full-title] The Journal of clinical psychiatry
  • [ISO-abbreviation] J Clin Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 0
  •  go-up   go-down


85. Westermeyer J, Canive J, Thuras P, Kim SW, Crosby R, Thompson J, Garrard J: Remission from pathological gambling among Hispanics and Native Americans. Community Ment Health J; 2006 Dec;42(6):537-53
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission from pathological gambling among Hispanics and Native Americans.
  • This community survey studied remission from pathological gambling (PG) among American Indian (AI) and Hispanic American (HA) veterans.
  • Remission was defined as having a lifetime diagnosis of PG, but no gambling symptoms in the last year.
  • Remission was associated with absence of a current Axis 1 diagnosis, especially absence of a current post-traumatic stress disorder.
  • [MeSH-major] Disruptive, Impulse Control, and Conduct Disorders / diagnosis. Gambling / psychology. Hispanic Americans / psychology. Indians, North American / psychology. Veterans / psychology
  • [MeSH-minor] Adult. Aged. Anxiety Disorders / diagnosis. Anxiety Disorders / psychology. Anxiety Disorders / therapy. Combat Disorders / diagnosis. Combat Disorders / psychology. Combat Disorders / therapy. Comorbidity. Depressive Disorder / diagnosis. Depressive Disorder / psychology. Depressive Disorder / therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Midwestern United States. Self-Help Groups. Southwestern United States. Treatment Outcome


86. Greenstein DK, Wolfe S, Gochman P, Rapoport JL, Gogtay N: Remission status and cortical thickness in childhood-onset schizophrenia. J Am Acad Child Adolesc Psychiatry; 2008 Oct;47(10):1133-40
Hazardous Substances Data Bank. CLOZAPINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Remission status and cortical thickness in childhood-onset schizophrenia.
  • In this study, remission status at the time of discharge was examined in relation to admission cortical thickness for childhood-onset schizophrenia probands.
  • METHOD: The relation between admission cortical brain thickness on magnetic resonance imaging and remission status at the time of discharge an average of 3 months later was examined for 56 individuals (32 males) ages 6 to 19 diagnosed with childhood-onset schizophrenia.
  • Discharge remission criteria were adapted from the 2005 Remission in Schizophrenia Working Group criteria.
  • CONCLUSIONS: Our results provide neuroanatomic correlates of clinical remission in schizophrenia and evidence that response to treatment may be mediated by these cortical brain regions.
  • [MeSH-major] Cerebral Cortex / pathology. Clozapine / therapeutic use. Image Processing, Computer-Assisted. Magnetic Resonance Imaging. Schizophrenia / diagnosis. Schizophrenia / therapy. Schizophrenic Psychology

  • Genetic Alliance. consumer health - Childhood-Onset Schizophrenia.
  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Image Anal. 2004 Sep;8(3):311-23 [15450225.001]
  • [Cites] Arch Gen Psychiatry. 1983 Nov;40(11):1228-31 [6639293.001]
  • [Cites] Biol Psychiatry. 1992 Feb 1;31(3):241-54 [1547298.001]
  • [Cites] J Am Acad Child Adolesc Psychiatry. 1994 Jun;33(5):636-44 [8056726.001]
  • [Cites] Arch Gen Psychiatry. 1996 Dec;53(12):1090-7 [8956674.001]
  • [Cites] IEEE Trans Med Imaging. 1998 Feb;17(1):87-97 [9617910.001]
  • [Cites] Arch Gen Psychiatry. 1999 Jul;56(7):649-54 [10401513.001]
  • [Cites] Neuroimage. 2005 Jan 1;24(1):163-73 [15588607.001]
  • [Cites] Am J Psychiatry. 2005 Mar;162(3):441-9 [15741458.001]
  • [Cites] Mol Psychiatry. 2005 May;10(5):434-49 [15700048.001]
  • [Cites] Cereb Cortex. 2005 Jul;15(7):995-1001 [15537673.001]
  • [Cites] Neuroimage. 2005 Aug 1;27(1):210-21 [15896981.001]
  • [Cites] Psychiatry Res. 2005 Nov 30;140(2):147-55 [16256315.001]
  • [Cites] Nature. 2006 Mar 30;440(7084):676-9 [16572172.001]
  • [Cites] Neuroimage. 2006 Jun;31(2):572-84 [16503170.001]
  • [Cites] Arch Gen Psychiatry. 2006 Jul;63(7):721-30 [16818861.001]
  • [Cites] Am J Psychiatry. 2006 Nov;163(11):2000-2 [17074953.001]
  • [Cites] J Child Psychol Psychiatry. 2006 Oct;47(10):1003-12 [17073979.001]
  • [Cites] J Clin Psychopharmacol. 2006 Dec;26(6):571-8 [17110813.001]
  • [Cites] Int Clin Psychopharmacol. 2007 Jan;22(1):51-5 [17159460.001]
  • [Cites] Schizophr Res. 2007 Jan;89(1-3):129-39 [17095194.001]
  • [Cites] J Clin Psychiatry. 2006 Nov;67(11):1707-12 [17196049.001]
  • [Cites] Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):510-6 [17239513.001]
  • [Cites] Eur Psychiatry. 2007 Mar;22(2):129-36 [17129711.001]
  • [Cites] Brain. 2007 Mar;130(Pt 3):693-707 [17347256.001]
  • [Cites] Arch Gen Psychiatry. 2007 Jul;64(7):772-80 [17606811.001]
  • [Cites] J Neurosci. 2008 Apr 2;28(14):3586-94 [18385317.001]
  • [Cites] Biol Psychiatry. 1999 Nov 15;46(10):1418-28 [10578456.001]
  • [Cites] Psychiatry Res. 1998 Dec 14;84(2-3):75-88 [10710165.001]
  • [Cites] Br J Psychiatry. 1999 Nov;175:444-51 [10789276.001]
  • [Cites] Arch Gen Psychiatry. 2000 Aug;57(8):761-8 [10920464.001]
  • [Cites] Neuroimage. 2000 Sep;12(3):340-56 [10944416.001]
  • [Cites] Neuroimage. 2001 Feb;13(2):375-80 [11162277.001]
  • [Cites] Arch Gen Psychiatry. 2001 Mar;58(3):289-95 [11231836.001]
  • [Cites] Biol Psychiatry. 2001 Mar 15;49(6):487-99 [11257234.001]
  • [Cites] Schizophr Res. 2001 Apr 15;49(1-2):1-52 [11343862.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11650-5 [11573002.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Oct;21(10):1280-91 [12585710.001]
  • [Cites] Biol Psychiatry. 2003 Sep 15;54(6):608-15 [13129655.001]
  • [Cites] Schizophr Res. 2003 Nov 1;64(1):41-52 [14511800.001]
  • [Cites] Am J Psychiatry. 2003 Dec;160(12):2181-9 [14638588.001]
  • [CommentIn] J Am Acad Child Adolesc Psychiatry. 2008 Oct;47(10):1103-4 [20566186.001]
  • (PMID = 18724254.001).
  • [ISSN] 1527-5418
  • [Journal-full-title] Journal of the American Academy of Child and Adolescent Psychiatry
  • [ISO-abbreviation] J Am Acad Child Adolesc Psychiatry
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / Z99 MH999999
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents; J60AR2IKIC / Clozapine
  • [Other-IDs] NLM/ NIHMS84659; NLM/ PMC3430080
  •  go-up   go-down


87. Kwon EJ, Yamagami J, Nishikawa T, Amagai M: Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission. J Eur Acad Dermatol Venereol; 2008 Sep;22(9):1070-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anti-desmoglein IgG autoantibodies in patients with pemphigus in remission.
  • Whereas ELISA index values fluctuate in parallel with disease activity, ELISA positivity during clinical remission has been observed.
  • OBJECTIVE: To determine the prevalence of positive Dsg ELISA index values during clinical remission.
  • To ascertain how positive Dsg ELISA scores during remission compare with those during active disease.
  • METHODS: Dsg ELISA was performed on serum samples of PV and PF patients taken during remission (lesion-free >or= 3 months on <or= 15 mg or <or= 5 mg/day prednisolone) and active disease.
  • RESULTS: When remission was defined as no eruption >or= 3 months with <or= 15 mg/day prednisolone, 20 of 43 PV patients (46.5%) and 4 of 12 PF patients (33.3%) showed Dsg3 and Dsg1 ELISA positivity, respectively.
  • The index value of each ELISA-positive remission serum was consistently lower than that of its corresponding active disease serum.
  • CONCLUSIONS: Circulating anti-Dsg IgG autoantibodies are found in a considerable percentage of pemphigus patients in remission, who have high levels of antibody production during active stages.


88. Do VT, Baird BG, Kockler DR: Probiotics for maintaining remission of ulcerative colitis in adults. Ann Pharmacother; 2010 Mar;44(3):565-71
MedlinePlus Health Information. consumer health - Ulcerative Colitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probiotics for maintaining remission of ulcerative colitis in adults.
  • OBJECTIVE: To evaluate evidence for probiotic efficacy for maintaining remission of ulcerative colitis (UC) in adults.
  • Two open-label and 3 double-blind randomized trials evaluated probiotic efficacy for maintaining remission of UC.
  • Clinical and surrogate markers for maintaining remission of UC were assessed.
  • CONCLUSIONS: Studies evaluating probiotics for maintaining remission of UC are limited by trial design and use of different probiotics with variable bacterial contents.
  • To answer these questions, large, randomized, controlled trials need to be conducted before probiotics can be routinely recommended for maintaining remission of UC.
  • [MeSH-minor] Adult. Bifidobacterium. Clinical Trials as Topic. Escherichia coli. Humans. Lactobacillus rhamnosus. Remission Induction / methods. Secondary Prevention. Treatment Outcome

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124461.001).
  • [ISSN] 1542-6270
  • [Journal-full-title] The Annals of pharmacotherapy
  • [ISO-abbreviation] Ann Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


89. Cervantes-Castaneda RA, Bhat P, Fortuna E, Acevedo S, Foster CS: Induction of durable remission in ocular inflammatory diseases. Eur J Ophthalmol; 2009 Jan-Feb;19(1):118-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of durable remission in ocular inflammatory diseases.
  • PURPOSE: To describe a paradigm of care for patients with ocular inflammatory diseases aimed at induction of durable remission.
  • Durable remission was defined as control of inflammation in the absence of systemic IMT for at least 1 year.
  • Thirty percent of the patients required at least 2 years of therapy with systemic IMT to obtain durable remission, while 44% required 2 to 5 years of therapy to achieve the same.
  • Twenty percent continued to stay in remission, off immunomodulatory drugs, between 2 and 5 years and 18% were in remission for more than 5 years after therapy discontinuation.
  • Durable drug-free remission is an achievable goal, and should be pursued by ocular inflammatory disease specialists.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123158.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Immunosuppressive Agents
  •  go-up   go-down


90. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M: Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev; 2009;(1):CD000067
Hazardous Substances Data Bank. MERCAPTOPURINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease.
  • A meta-analysis was performed to evaluate the efficacy of these agents for the maintenance of remission of quiescent Crohn's disease.
  • OBJECTIVES: To assess the efficacy of azathioprine and 6-mercaptopurine for maintenance of remission in quiescent Crohn's disease.
  • Peto odds ratios and 95% confidence intervals for maintenance of remission, steroid sparing, and withdrawals due to adverse effects were calculated.
  • Numbers needed to treat or harm (NNT, NNH respectively) for the maintenance of remission, steroid sparing, and withdrawals due to adverse effects were also determined.
  • Azathioprine and 6-mercaptopurine had a positive effect on maintaining remission.
  • The Peto odds ratio (OR) for maintenance of remission with azathioprine was 2.32 (95% CI 1.55 to 3.49) with a NNT of 6.
  • The Peto OR for maintenance of remission with 6-mercaptopurine was 3.32 (95% CI 1.40 to 7.87) with a of 4.
  • AUTHORS' CONCLUSIONS: Azathioprine and 6-mercaptopurine are more effective than placebo for maintenance of remission in Crohn's disease.
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • Hazardous Substances Data Bank. AZATHIOPRINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2015;10:CD000067 [26517527.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2000;(2):CD000067 [10796482.001]
  • (PMID = 19160175.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 0 / Prodrugs; E7WED276I5 / 6-Mercaptopurine; MRK240IY2L / Azathioprine
  • [Number-of-references] 36
  •  go-up   go-down


91. Gipson DS, Chin H, Presler TP, Jennette C, Ferris ME, Massengill S, Gibson K, Thomas DB: Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol; 2006 Mar;21(3):344-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential risk of remission and ESRD in childhood FSGS.
  • In order to assess the risk of progression of children with primary FSGS and the impact of proteinuria remission status on disease progression, we undertook this study to describe a cohort of 60 children and adolescents from the Glomerular Disease Collaborative Network.
  • Complete remission was achieved in 20%, partial remission in 33%, and 47% have not achieved remission during follow-up with all prescribed therapy.
  • Only ACE-I/ARB therapy was predictive of proteinuria remission in multivariate analysis (hazard ratio [HR] 3.35; 95% confidence interval [CI] 1.42-7.92).
  • Renal survival was much improved in patients with complete or partial remission compared with no remission in univariate analysis.
  • In multivariate analysis comparing no remission status, complete remission was associated with a 90% decreased risk of ESRD (HR 0.10, 95% CI 0.01-0.79, p =0.03).
  • In summary, proteinuria remission status is a valid predictor of long-term renal survival in children with FSGS.
  • [MeSH-minor] Adolescent. Angiotensin Receptor Antagonists. Angiotensin-Converting Enzyme Inhibitors / therapeutic use. Child. Cohort Studies. Disease Progression. Glomerular Filtration Rate. Humans. Nephrotic Syndrome / etiology. Prognosis. Proteinuria / etiology. Remission Induction. Risk Factors

  • MedlinePlus Health Information. consumer health - Kidney Failure.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395603.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Angiotensin Receptor Antagonists; 0 / Angiotensin-Converting Enzyme Inhibitors
  •  go-up   go-down


92. Kane JM: An evidence-based strategy for remission in schizophrenia. J Clin Psychiatry; 2008;69 Suppl 3:25-30
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An evidence-based strategy for remission in schizophrenia.
  • Remission may even be considered a potentially realistic goal.
  • This article briefly reviews the status of remission as a therapeutic goal in the treatment of schizophrenia and summarizes available treatment research reporting remission and recovery as clinical outcomes.
  • [MeSH-minor] Antipsychotic Agents / therapeutic use. Humans. Remission Induction. Secondary Prevention

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18533759.001).
  • [ISSN] 1555-2101
  • [Journal-full-title] The Journal of clinical psychiatry
  • [ISO-abbreviation] J Clin Psychiatry
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  • [Number-of-references] 47
  •  go-up   go-down


93. Mosca M, Bombardieri S: Assessing remission in systemic lupus erythematosus. Clin Exp Rheumatol; 2006 Nov-Dec;24(6 Suppl 43):S-99-104
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing remission in systemic lupus erythematosus.
  • However, criteria for disease remission have not been clearly established for these indices, except for the SLE Disease Activity Index (SLEDAI).
  • Defining remission in SLE in an objective manner depends on reaching agreement on the relative importance of systemic activity, damage, QoL, and laboratory tests, as well as activity and damage of specific organs.
  • [MeSH-minor] Clinical Trials as Topic. Humans. Quality of Life. Remission Induction

  • Genetic Alliance. consumer health - Lupus.
  • Genetic Alliance. consumer health - Systemic lupus erythematosus.
  • MedlinePlus Health Information. consumer health - Lupus.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17083771.001).
  • [ISSN] 0392-856X
  • [Journal-full-title] Clinical and experimental rheumatology
  • [ISO-abbreviation] Clin. Exp. Rheumatol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 47
  •  go-up   go-down


94. Mochizuki H, Muramatsu R, Hagiwara S, Takami S, Mizuno T, Arakawa H: Relationship between bronchial hyperreactivity and asthma remission during adolescence. Ann Allergy Asthma Immunol; 2009 Sep;103(3):201-5
MedlinePlus Health Information. consumer health - Asthma in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between bronchial hyperreactivity and asthma remission during adolescence.
  • Twenty-eight children had symptom-free adolescent asthma (i.e., remission asthma) (boy to girl ratio, 16:12; mean age, 14.6 years), 25 had intermittent adolescent asthma (boy to girl ratio, 16:9; mean age, 14.9 years), and 47 had symptomatic adolescent asthma (boy to girl ratio, 27:20; mean age, 12.7 years).
  • RESULTS: There was no significant difference in lung function results, such as forced vital capacity and forced expiratory volume in 1 second, between the intermittent asthma and the remission asthma groups.
  • However, the value of Sm of the remission asthma group was significantly lower than that of the intermittent asthma group (P = .02) and the symptomatic asthma group (P = .02).
  • CONCLUSIONS: These data show that the adolescents with asthma remission showed a significant decrease of Sm, whereas Dmin was not changed.
  • [MeSH-minor] Adolescent. Adolescent Development / physiology. Bronchoconstriction. Child. Child, Preschool. Female. Humans. Male. Methacholine Chloride. Puberty. Remission, Spontaneous. Vital Capacity. Young Adult

  • Genetic Alliance. consumer health - Asthma.
  • MedlinePlus Health Information. consumer health - Asthma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19788016.001).
  • [ISSN] 1081-1206
  • [Journal-full-title] Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • [ISO-abbreviation] Ann. Allergy Asthma Immunol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0W5ETF9M2K / Methacholine Chloride
  •  go-up   go-down


95. Schutte KK, Moos RH, Brennan PL: Predictors of untreated remission from late-life drinking problems. J Stud Alcohol; 2006 May;67(3):354-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predictors of untreated remission from late-life drinking problems.
  • OBJECTIVE: Studies of mixed-aged samples have suggested that a majority of problem drinkers achieve remission "naturally", without formal treatment.
  • We sought to describe the life history predictors of untreated remission among older adults.
  • RESULTS: A majority (73%) of remitted, older problem drinkers attained remission without any formal treatment for drinking problems.
  • CONCLUSIONS: Many late-life problem drinkers with milder drinking problems achieve remission without treatment or advice to reduce consumption.

  • MedlinePlus Health Information. consumer health - Alcohol.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Stud Alcohol. 1983 Sep;44(5):911-7 [6645551.001]
  • [Cites] Acta Psychiatr Scand. 1987 May;75(5):495-9 [3604734.001]
  • [Cites] J Stud Alcohol. 1990 Jan;51(1):68-76 [2299853.001]
  • [Cites] Br J Addict. 1990 Sep;85(9):1177-85 [2224198.001]
  • [Cites] Psychol Aging. 1990 Dec;5(4):491-501 [2278671.001]
  • [Cites] J Subst Abuse. 1991;3(4):395-404 [1821293.001]
  • [Cites] Addict Behav. 1992;17(4):347-58 [1502968.001]
  • [Cites] Arch Gen Psychiatry. 1993 Feb;50(2):85-94 [8427558.001]
  • [Cites] Alcohol Clin Exp Res. 1993 Apr;17(2):217-24 [8488958.001]
  • [Cites] Addict Behav. 1993 Sep-Oct;18(5):529-42 [8310872.001]
  • [Cites] J Stud Alcohol. 1994 Mar;55(2):133-40 [8189733.001]
  • [Cites] J Stud Alcohol. 1994 Jul;55(4):401-11 [7934047.001]
  • [Cites] J Stud Alcohol. 1994 Nov;55(6):660-6 [7861793.001]
  • [Cites] Addict Behav. 1995 Jul-Aug;20(4):427-41 [7484324.001]
  • [Cites] Am J Epidemiol. 1996 Jan 15;143(2):177-86 [8546119.001]
  • [Cites] Am J Public Health. 1996 Jul;86(7):966-72 [8669520.001]
  • [Cites] Int J Addict. 1995 Nov-Dec;30(13-14):1693-716 [8751316.001]
  • [Cites] J Subst Abuse. 1996;8(4):453-62 [9058357.001]
  • [Cites] J Fam Pract. 1999 May;48(5):378-84 [10334615.001]
  • [Cites] J Stud Alcohol. 1999 Jul;60(4):463-6 [10463801.001]
  • [Cites] J Subst Abuse Treat. 2000 Mar;18(2):169-77 [10716100.001]
  • [Cites] Addiction. 2000 May;95(5):749-64 [10885050.001]
  • [Cites] Addiction. 2000 May;95(5):765-75 [10885051.001]
  • [Cites] J Stud Alcohol. 1985 Jan;46(1):53-8 [3974236.001]
  • [Cites] Int J Addict. 1986 Jan;21(1):1-23 [3710636.001]
  • [Cites] Am J Drug Alcohol Abuse. 2000 Aug;26(3):443-60 [10976668.001]
  • [Cites] J Stud Alcohol. 2000 Nov;61(6):783-6 [11188482.001]
  • [Cites] J Stud Alcohol. 2001 May;62(3):322-34 [11414342.001]
  • [Cites] Addiction. 2001 Sep;96(9):1327-36 [11672497.001]
  • [Cites] Subst Use Misuse. 2001 Sep;36(11):1417-41 [11693950.001]
  • [Cites] Subst Use Misuse. 2001 Sep;36(11):1501-18 [11693953.001]
  • [Cites] Subst Use Misuse. 2001 Sep;36(11):1543-70 [11693955.001]
  • [Cites] Arch Gen Psychiatry. 2001 Nov;58(11):1065-71 [11695954.001]
  • [Cites] Alcohol Clin Exp Res. 2002 Jun;26(6):936-48 [12068264.001]
  • [Cites] Addiction. 2003 Jul;98(7):901-11 [12814496.001]
  • [Cites] Alcohol Res Health. 2002;26(4):308-15 [12875042.001]
  • [Cites] J Stud Alcohol. 2004 Jul;65(4):428-33 [15376816.001]
  • [Cites] J Abnorm Psychol. 1982 Jun;91(3):199-209 [7096790.001]
  • (PMID = 16608144.001).
  • [ISSN] 0096-882X
  • [Journal-full-title] Journal of studies on alcohol
  • [ISO-abbreviation] J. Stud. Alcohol
  • [Language] ENG
  • [Grant] United States / NIAAA NIH HHS / AA / AA06699; United States / NIAAA NIH HHS / AA / AA006699-15; United States / NIAAA NIH HHS / AA / R01 AA015685; United States / NIAAA NIH HHS / AA / R01 AA012718; United States / NIAAA NIH HHS / AA / R01 AA006699; United States / NIAAA NIH HHS / AA / R01 AA015685-01A1; United States / NIAAA NIH HHS / AA / R01 AA006699-15; United States / NIAAA NIH HHS / AA / AA12718; United States / NIAAA NIH HHS / AA / AA015685-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS25123; NLM/ PMC1941658
  •  go-up   go-down


96. Butterworth AD, Thomas AG, Akobeng AK: Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst Rev; 2008;(3):CD006634
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Probiotics for induction of remission in Crohn's disease.
  • OBJECTIVES: To determine if there is any evidence for the efficacy of probiotics for the induction of remission in Crohn's disease.
  • SELECTION CRITERIA: Randomised controlled trials (RCTs) that compared probiotics against placebo or any other intervention for the induction of remission in Crohn's disease were eligible for inclusion.
  • The main outcome measure was the occurrence of clinical remission.
  • Four of 5 patients in the probiotic group achieved remission compared to 5 of 6 in the placebo group (OR 0.80; 95% CI 0.04 to 17.20).
  • AUTHORS' CONCLUSIONS: There is insufficient evidence to make any conclusions about the efficacy of probiotics for induction of remission in Crohn's disease.
  • [MeSH-minor] Humans. Randomized Controlled Trials as Topic. Remission Induction


97. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH: Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev; 2008;(3):CD000296
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Budesonide for induction of remission in Crohn's disease.
  • BACKGROUND: Corticosteroids play a key role in the induction of remission in Crohn's disease.
  • OBJECTIVES: The primary objective was to evaluate the efficacy and safety of oral budesonide for the induction of remission in Crohn's disease.
  • The primary outcome was induction of remission (CDAI < 150) by week 8 to 16 of treatment.
  • Secondary outcomes included: time to remission, mean change in CDAI, clinical, histological or endoscopic improvement, improvement in quality of life, adverse events and early withdrawal.
  • After 8 weeks of treatment, budesonide was significantly more effective than placebo (RR 1.96, 95% CI 1.19 to 3.23) or mesalamine (RR 1.63; 95% CI 1.23 to 2.16) for induction of remission.
  • Budesonide was significantly less effective than conventional steroids for induction of remission (RR 0.86, 95% CI 0.76 to 0.98), particularly among patients with severe disease (CDAI > 300) (RR 0.52, 95% CI 0.28 to 0.95).
  • AUTHORS' CONCLUSIONS: Budesonide is more effective than placebo or mesalamine for induction of remission in Crohn's disease.
  • [MeSH-minor] Administration, Oral. Humans. Randomized Controlled Trials as Topic. Remission Induction

  • Genetic Alliance. consumer health - Crohn Disease.
  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [UpdateIn] Cochrane Database Syst Rev. 2015;6:CD000296 [26039678.001]
  • [UpdateOf] Cochrane Database Syst Rev. 2005;(4):CD000296 [16235274.001]
  • (PMID = 18646064.001).
  • [ISSN] 1469-493X
  • [Journal-full-title] The Cochrane database of systematic reviews
  • [ISO-abbreviation] Cochrane Database Syst Rev
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 51333-22-3 / Budesonide
  • [Number-of-references] 70
  •  go-up   go-down


98. Leucht S, Beitinger R, Kissling W: On the concept of remission in schizophrenia. Psychopharmacology (Berl); 2007 Nov;194(4):453-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] On the concept of remission in schizophrenia.
  • RATIONALE: Criteria for remission in schizophrenia have recently been presented.
  • OBJECTIVES AND METHODS: We re-analysed seven anti-psychotic drug trials (n = 1,708) of patients with schizophrenia to find out how many met the new remission criteria and their single components, how many met two previously used remission criteria, and how many met simpler measures of response (at least 50% Brief Psychiatric Rating Scale [BPRS] reduction, a Clinical Global Impressions [CGI] improvement score of at least 'much better' or a CGI severity score of 'mild or better').
  • RESULTS: Thirty-seven percent/41% (last observation carried forward [LOCF]/completer analysis [CO]) of the initially acutely ill patients with positive symptoms met the severity criteria of remission at 4 weeks, and 27%/52% (worst case/CO) met the severity and time criteria at 1 year.
  • ' However, the definition 'CGI severity score mild or better' was of a stringency similar to the new remission criteria, which probably explains why fewer patients met previously defined criteria that included this scale.
  • CONCLUSION: The new remission criteria proved to be an achievable goal for clinical trials.
  • [MeSH-minor] Brief Psychiatric Rating Scale / statistics & numerical data. Diagnostic and Statistical Manual of Mental Disorders. Dose-Response Relationship, Drug. Humans. Randomized Controlled Trials as Topic. Remission Induction. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Schizophrenia.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17618422.001).
  • [ISSN] 0033-3158
  • [Journal-full-title] Psychopharmacology
  • [ISO-abbreviation] Psychopharmacology (Berl.)
  • [Language] eng
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antipsychotic Agents
  •  go-up   go-down


99. Addington J, Addington D: Symptom remission in first episode patients. Schizophr Res; 2008 Dec;106(2-3):281-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Symptom remission in first episode patients.
  • Recently, new remission criteria for schizophrenia has been proposed, based on low symptom severity of core symptoms (the severity criteria), which is sustained over a minimum of 6 months (time criterion).
  • Eighty-eight subjects (36.7%) met both the severity criteria and time criteria for remission (in-remission group); 47 subjects (19.6%) met only the severity criteria at their most recent assessment (severity only group); 49 (20.4%) subjects had met severity criteria at one or more assessments but did not meet severity or severity and time at the most recent assessment (fluctuating group); and 56 (23.3%) did not meet remission criteria (non-remission group).
  • Those who achieved remission had lower levels of symptoms and higher functioning at baseline and at the final follow-up assessment, improved premorbid functioning, shorter duration of untreated psychosis and increased changes in symptoms over time.
  • [MeSH-major] Psychiatric Status Rating Scales / statistics & numerical data. Psychotic Disorders / diagnosis. Schizophrenia / diagnosis. Schizophrenic Psychology. Severity of Illness Index

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • MedlinePlus Health Information. consumer health - Schizophrenia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18926666.001).
  • [ISSN] 0920-9964
  • [Journal-full-title] Schizophrenia research
  • [ISO-abbreviation] Schizophr. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


100. Moos RH, Moos BS: Paths of entry into alcoholics anonymous: consequences for participation and remission. Alcohol Clin Exp Res; 2005 Oct;29(10):1858-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paths of entry into alcoholics anonymous: consequences for participation and remission.
  • They also described their reasons for entering AA and/or treatment and the perceived benefits of these sources of help RESULTS: Compared with individuals who initially participated only in treatment but later entered AA, those who entered treatment and AA together participated in AA longer and more frequently and were more likely to achieve remission.
  • Among individuals who initially participated only in AA, those who later entered treatment had poorer remission outcomes than those who did not enter treatment.
  • Longer duration of participation in AA was associated with a higher likelihood of remission at all four follow-ups; individuals who dropped out of AA were more likely to relapse or remain nonremitted.
  • CONCLUSIONS: Compared with individuals who participated only in professional treatment in the first year after they initiated help-seeking, individuals who participated in both treatment and AA were more likely to achieve remission.

  • MedlinePlus Health Information. consumer health - Alcoholism and Alcohol Abuse.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16269916.001).
  • [ISSN] 0145-6008
  • [Journal-full-title] Alcoholism, clinical and experimental research
  • [ISO-abbreviation] Alcohol. Clin. Exp. Res.
  • [Language] eng
  • [Grant] United States / NIAAA NIH HHS / AA / AA12718
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down






Advertisement